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ABSTRACT OF THE DISSERTATION 
 
Cell Membrane-Coated Nanoparticles for Immune Modulation 
 
by 
 
Ashley Kroll 
 
Doctor of Philosophy in NanoEngineering 
 
University of California San Diego, 2019 
 
Professor Liangfang Zhang, Chair 
  
Nanotechnology is an exciting scientific area that is changing the way we 
design and administer medicines. One avenue in which nanomedicine can have a 
large impact is through immune modulation and “nano-immunoengineering”.  
Nanoparticle size, design freedoms, and unique cell-particle interactions can be 
taken advantage of to influence the immune system in new and efficacious ways. 
  
xvii 
This dissertation will demonstrate how cell membrane coating can be merged with 
nanoparticle design to facilitate immune modulation for the improvement of a 
variety of pathological conditions. The rationale for cell membrane coating and the 
use of nanoparticles in immune modulation will be discussed in the first chapter of 
the dissertation. 
The second portion of the dissertation will focus on the design of cancer cell 
membrane-coated nanoparticles for anticancer vaccination. The nanovaccine is 
designed to include multi-antigenic cancer cell membranes wrapped around an 
immune-stimulating nanoparticle core. The codelivery of both components to the 
lymphatic system then directs the formation of a strong and specific anticancer 
immunity. The third portion of the dissertation will concentrate on the development 
of erythrocyte membrane-coated nanoparticles for antivirulence vaccination. 
Membrane-disrupting pore-forming toxins naturally embed into the red blood cell 
membrane coating of the nanoparticles. The nanoparticle-bound toxins are then 
safely delivered to immune cells for antigenic processing, driving the generation of 
potent anti-toxin antibodies and immunity. Finally, the fourth section of this 
dissertation will focus on the use of platelet membrane-coated “nanosponges” as a 
therapy for clearing autoantibodies. The platelet membrane coating on the 
nanoparticle accurately mimics the surface of a real platelet to enable the absorption 
of anti-platelet antibodies. The bound antibodies are then rendered harmless to real 
platelets and are cleared in a nanoparticle form, ultimately reducing autoimmune 
disease symptoms.  
  
xviii 
This dissertation will serve as an example of rationally engineering cell 
membrane-coated nanoparticles to enhance the ability of the immune system to 
resolve different immunological challenges. By harnessing these tools, cell 
membrane-coated nanoparticles can have a great impact in the field of 
immunotherapy, and have much potential to be expanded upon for new therapeutic 
and prophylactic modalities.  
 
 
 
 1 
Chapter 1 
Introduction 
 
 
 2 
1.1 Introduction 
 
Our immune system is a complex network of cells, proteins, and physical 
barriers that work together to keep the human body free from disease. When 
mobilized correctly, it has the ability to seek out and eliminate foreign invaders 
with exquisite specificity. Malfunctioning or underperforming immunity is often 
the root cause of many disease states. For example, an overactive immune system 
can result in autoimmunity, which is characterized by proinflammatory states and 
leads to the destruction of healthy tissue [1, 2]. On the other hand, an underactive 
immune system can lead to enhanced susceptibility to infection, which is becoming 
increasingly dangerous given the rise of antibiotic resistance [3].  With regards to 
tumorigenesis, it has been shown that the immune system is integral in helping to 
prevent the proliferation of malignant cells [4].  It is now known that for tumors to 
successfully grow, cancerous cells must generally go through a prolonged 
evolutionary process in order to develop mechanisms for immune evasion 
[5].  Tumors can manipulate the surrounding microenvironment to support growth 
and suppress host immune responses using cytokine and growth factor secretion 
[6],  extracellular matrix restructuring [7],  and cellular signaling [8, 9].  It is for 
this reason that an intense amount of research has been focused on leveraging the 
immune system to fight off cancer [10].  In general, cancer immunotherapies seek 
to train, augment, or supplement the body's own ability to eliminate malignant 
growths. There are numerous classes of immunotherapy, and they can act on 
 
 
 3 
different stages of immunity, ranging from initial antigen presentation up to the 
final effector stages [11, 12].  Depending on the specific type of cancer being 
treated, early returns have thus far been promising, and a number of 
immunotherapies have proven to be highly potent in scenarios where the previous 
clinical standard of care had little effect [13-15]. 
Anticancer vaccination is a class of cancer immunotherapy that focuses 
largely on training the immune system to recognize and mount a response against 
tumors in an antigen‐specific manner [12, 16].  Over the course of recent human 
history, vaccines have represented an attractive means of managing the spread of 
disease, as most are easy to administer and can promote the development of 
sterilizing immunity [17].  Particularly in the case infectious diseases, vaccination 
has proven to be highly effective, having likely helped to prevent millions of deaths 
as a result of large‐scale prophylaxis campaigns [18].   Despite the favorable history 
of antibacterial and antiviral vaccines, anticancer vaccination unfortunately has not 
achieved the same level of success [19, 20].  Unlike with those against pathogens, 
there are additional hurdles that must be overcome in order for vaccines against 
tumors to be effective. One of the main challenges comes from the fact that most 
tumors are lowly immunogenic and originate from one's own healthy cells. As such, 
it is incredibly difficult for the immune system to correctly identify malignant 
tissue. Additionally, vaccines against established tumors must be administered 
therapeutically, requiring the need for formulations that are highly potent in 
addition to being tumor‐specific. This has oftentimes necessitated the use of 
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complex strategies for immune system manipulation [19-21],  many of which are 
lowly viable in a clinical setting given poor cost‐to‐benefit ratios. In 2010, the 
United States Food and Drug Administration approved the first and only therapeutic 
anticancer vaccine, sipuleucel‐T [22].  This autologous cell‐based therapy trains 
patient‐derived immune cells against a common prostate cancer antigen before 
reinfusion of the cells back into the patient. The treatment has been shown to 
marginally increase patient survival time, but the complex logistics and high cost 
of manufacturing a personalized cell‐based vaccine have limited its commercial 
viability. 
To address the hurdles faced by traditional vaccination schemes against 
cancer, many researchers have turned toward nanotechnology to help guide the 
design of nanovaccines capable of producing potent, specific, and durable 
antitumor responses [23, 24].  Compared with traditional vaccines, those 
manufactured at the nanoscale have unique physical and material properties that 
make them better suited for immune manipulation. Through purposeful 
engineering, nanovaccines can be formulated with antigen and adjuvant payloads 
in a manner that maximizes immune responses through efficient delivery to specific 
cellular subsets. Ultimately, the goal is to leverage such platforms for the controlled 
programing of endogenous immunity to reverse tumor burden. In this review, we 
start by covering some basic background information regarding anticancer vaccines 
and the current state of traditional platforms. We then discuss developments in the 
field of anticancer nanovaccines, focusing on platforms for both nonspecific and 
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antigen‐specific immune modulation. Finally, we introduce an emerging class of 
biomimetic nanoparticles based on cell membrane coating nanotechnology. This 
top‐down strategy directly leverages nature's own design principles as a means of 
fabricating multifunctional and multiantigenic nanosystems, which have the 
potential to play an important role in the future of anticancer vaccination. 
 
1.2 Background on Anticancer Vaccination 
 
1.2.1 Cancer Immunology and Immunotherapy 
 
Cancer is generally characterized by an accumulation of mutations that 
allows for uncontrolled cell proliferation. As tumors grow, they are in a constant 
battle with the immune system and must evolve mechanisms for escape over time 
[5].  Due to the random nature of the mutations that lead to malignancy, phenotypes 
can vary greatly among different cancers, as well as among cells within the same 
tumor. This heterogeneity not only serves as a challenge for traditional cancer 
therapeutics, but also acts as an immune evasion mechanism, increasing the 
likelihood of some mutant cell populations remaining undetected [20, 25].  Another 
immune escape mechanism occurs through antigen shedding [26]. As part of their 
normal growth, cells generate a large amount of waste products, and these 
unwanted products are commonly secreted through membrane vesicles. When 
released in large abundance, this process can also deplete the parent cell of tumor‐
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specific antigens, thus enabling the altered cancer cells to avoid destruction by 
cytotoxic T cells. Furthermore, shed antigens released into the bloodstream can act 
as decoys for neutralizing cancer‐specific antibodies. Solid tumors can employ 
additional means of escape, whereby their local microenvironments are remodeled 
to promote immune tolerance [27].  
A better understanding of how cancer interacts with the immune system has 
allowed for the development of new and effective therapeutics. The goal of cancer 
immunotherapies is to leverage a patient's own immune system to eradicate tumors 
in a highly specific and relatively safe manner [28].  One example is through an 
overall activation of the immune system by administering proinflammatory 
cytokines, which are immunomodulatory molecules released by activated immune 
cells [29, 30].  Although the immune stimulation caused by these molecules is 
nonspecific, an overall boost in immunity can sometimes strengthen immune cells 
enough to overcome tumor suppression. More specific, tumor‐targeted approaches 
can be achieved using genetically engineered chimeric antigen receptors (CAR) on 
T cells [31, 32].  In CAR T cell therapy, T lymphocytes are isolated from a patient 
or a donor through leukapheresis [33].  The cells are then genetically modified to 
express a receptor that can recognize tumor‐associated antigens, leading to 
elimination of the corresponding cells. Altered T cells are purified, expanded ex 
vivo, and finally infused back into patients for treatment. For some cancer types, 
this CAR approach has displayed striking efficacy in the clinic. 
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Antibodies have also been widely used to elicit antitumor immunity. For 
example, tumor‐targeted monoclonal antibodies that recognize tumor antigens can 
opsonize cancer cells and trigger antibody‐dependent, cell‐mediated cytotoxicity 
[34].  Furthermore, by conjugating antibodies with chemotherapeutics, these 
cytotoxic cargos can be more accurately targeted to the tumor site and induce 
immunogenic cell death [35].  More recently, antibody‐based checkpoint inhibitors 
have been used to directly modulate the function of specific immune cell subsets 
[36].  Immune checkpoints involve inhibitory receptors such as programed cell 
death protein 1 (PD1) and cytotoxic T lymphocyte–associated protein 4 (CTLA4) 
that regulate T cells. By presenting the corresponding ligands, the cytotoxic activity 
of T cells can be inhibited by tumor cells and regulatory immune cells. In 
checkpoint blockade therapy, antibodies target and block these receptor binding 
sites, thus removing the inhibitory signals on the T lymphocytes and unleashing 
their full potential for eliminating cancer cells. Despite their ability to elicit strong 
antitumor responses, efficacy of checkpoint blockades can vary greatly by patient 
[37].  This discrepancy may be explained by the fact that the therapy generally 
relies on the presence of preexisting tumor‐targeted T cells [38].  For this reason, 
checkpoint blockades are being actively explored for use in combination with other 
therapies such as anticancer vaccination, which can help to generate new T cell 
populations [39, 40].  
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1.2.2 Current State of Cancer Vaccines 
 
Cancer vaccines introduce tumor‐relevant antigenic material in a manner 
that leads to downstream mobilization of the immune system [28].  As the most 
immunogenic mutations have likely already been selected out by the time cancer is 
detected [5],  the presence of tumor antigens alone is usually not sufficient to drive 
proper immune stimulation. As such, tumor antigens are almost always combined 
with an adjuvant in order to enhance the immune response [41].  In the basic 
process, delivered antigens are taken up by professional antigen‐presenting cells 
(APCs), such as dendritic cells, which process and break down the antigens, 
followed by presentation of the peptide fragments via major histocompatibility 
complexes (MHCs) [42].  With the help of the adjuvant, the APCs mature, enabling 
engagement and activation of cancer‐relevant T cells. Finally, the activated T cells 
can help to promote tumor elimination, either by further propagating immune 
activation or by directly seeking out and destroying the cancer cells. 
Antigenic delivery to the immune system can be achieved in multiple ways. 
The most straightforward is the direct administration of tumor antigens. In single‐
antigen approaches, a tumor antigen overexpressed on cancer cells is administered 
parenterally [43].  This has been shown to elicit a robust immune response against 
the target antigen, especially in combination with an adjuvant; however, this 
approach may ultimately be thwarted by tumor heterogeneity. Whole cell 
preparations are another source of antigenic material that can theoretically be used 
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to vaccinate against the full breadth of tumor antigens [44].  However, this strategy 
often suffers from inadequate antitumor immune responses due to the interference 
from irrelevant proteins. In response to the often weak immunity generated by the 
above approaches, dendritic cells can be pulsed with an antigen and stimulated ex 
vivo [21].  Once this process is completed, the cells are then injected back into the 
patient in a process similar to CAR T cell therapy. The manipulated dendritic cells 
can subsequently migrate to the body's immune centers, where they train 
endogenous T cells. In a final method, antigenic uptake can happen in situ at the 
tumor site, taking advantage of processes such as immunogenic cell death, which 
provide autologous tumor antigens under an immunostimulatory context [45].  In 
situ vaccinations can also be achieved with oncolytic viruses that selectively infect 
and destroy cancer cells [46].  
In April of 2010, the United States Food and Drug Administration gave its 
first approval to a therapeutic anticancer vaccine, sipuleucel‐T, for the treatment of 
prostate cancer [47].  In this therapy, patient‐derived dendritic cells are pulsed with 
prostatic acid phosphatase, which is expressed in a significant number of patients 
with prostate cancer [48].  After exposure to the antigen, along with granulocyte‐
macrophage colony‐stimulating factor, the activated dendritic cells are introduced 
back into the patient. It was demonstrated in a clinical trial that sipuleucel‐T was 
able to extend median survival by 4.1 months, which paved the way for its eventual 
approval [47].  The successful translation of this treatment has motivated the further 
clinical exploration of anticancer vaccine formulations, and a search on 
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ClinicalTrials.gov yields over 200 results for active trials. Examples of current 
clinical studies include dendritic cell therapies for glioblastoma (NCT01808820), 
oncolytic viruses for ovarian cancer (NCT00408590), peptide vaccines for 
recurrent glioblastoma (NCT02754362), and whole cell vaccines for breast cancer 
(NCT00317603). 
Although cancer vaccines have had some success in the clinic, their limited 
ability to produce strong antitumor responses has hindered their widespread 
adoption. Despite its regulatory approval, the long‐term financial viability of 
sipuleucel‐T has come into question. The labor‐intensive processes involved in its 
manufacture necessitate its high cost, which may be hard to justify given that the 
treatment only modestly prolongs median survival. Single‐antigen peptide vaccines 
are able to elicit potent immune responses against the tumor cells that display the 
relevant antigenic epitopes; however, due to the heterogeneity of cancers, antigen‐
negative cells can eventually escape detection and proliferate without competition 
[20].  This approach is also not universal, and personalized identification and 
manufacture of vaccines based on tumor‐specific neoantigens may not yet be viable 
on a large scale [49, 50].  Whole cell vaccination with tumor lysates has the 
potential to elicit multiantigenic immunity, but the final immune response is often 
dampened by the presence of extraneous proteins [44].  This underscores the fact 
that, even when delivering the correct antigenic material, current vaccination 
strategies may not have sufficient immunostimulatory capacity to overcome the 
tolerogenic tumor microenvironment. 
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1.2.3 Advantages of Nanovaccines 
 
Nanotechnology offers many opportunities for improving the treatment 
efficacy of cancer vaccine formulations compared to traditional strategies (Figure 
1.1). A major advantage is the ability to formulate the antigen and adjuvant 
components together in a manner that maximizes immune stimulation 
[51].  Flexibility in nanoparticle synthesis methods and material choice allows for 
the incorporation of different classes of molecules, such as proteins, 
polysaccharides, nucleic acids, lipids, proteins, and polymers. For example, 
electrostatic interactions can be used to bind nanoparticles and payloads with 
opposite charges together [52],  or lipid‐based cargoes can be incorporated into the 
bilayer of liposomes through an insertion technique [53, 54].  Cargoes can also be 
encapsulated through chemical conjugation [55],  or they can be decorated onto the 
nanoparticle surface [56].  Oftentimes, the nanocarriers themselves can also be 
fabricated using biologically active vaccine components. For example, it has been 
demonstrated that both calcium phosphate [57],   a mineral‐based adjuvant, and 
certain antigen proteins [58] can be made into nanoparticulate form. 
Loading of antigen and adjuvant into nanoparticles can serve a variety of 
purposes. Encapsulation of vaccine components has been shown to increase 
immunogenicity by protecting the integrity of the molecules from enzymes in the  
body, such as nucleases, proteases, and phosphatases [59].  Nanoparticulate 
delivery not only protects the adjuvant from degradation, but can also protect the 
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body from the systemic toxicity of the adjuvants, which can cause side effects such 
as fever, lethargy, diarrhea, and nausea [60]. Nanoencapsulation can also be used 
to enhance immune responses by providing extended release properties. Certain 
gel‐like or polymeric nanoparticle platforms can act as depots, slowly releasing 
adjuvants and antigens over a long period of time [61].  Finally, there are a wide 
range of techniques available for loading both antigens and adjuvants into the same 
nanocarrier, which has been shown to dramatically increase antigen‐specific 
immune responses by unifying the pharmacokinetics of the coencapsulated 
payloads [51].  
In terms of payload delivery, nanoparticles can be designed to better target 
immune cells and immune‐rich organs. At their size range, nanoparticulate vaccine 
formulations more easily drain into the lymphatic system after administration, 
enabling efficient delivery to the lymph nodes [62, 63],  which contain high 
densities of immune cells. The localization of the nanoparticles can be further 
improved by modifying their outer layer to display ligands specific to immune cell 
surface receptors [64, 65].  Nanoformulations can also be designed to promote 
intracellular localization in a manner that maximizes the biological activity of the 
payloads. For example, nucleotide‐binding oligomerization domain–like agonists 
and small interfering RNA (siRNA) can be delivered directly to the cytosol using 
nanoparticles designed to penetrate through cell membranes [66],  and toll‐like 
receptors (TLRs) can be engaged by various agonists when delivered into cells via 
an endosomal pathway [67].  Overall, careful choices in the use of materials, 
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loading methods, and synthesis techniques for nanoparticle‐based formulations can 
all lead to improved vaccine efficacy. 
 
Figure 1.1: Advantages of nanoparticles for vaccine design. a) Various combinations 
of adjuvants and antigens can be formulated using nanoparticle platforms such as 
liposomes, emulsions, nanogels, and many others. b) Nanovaccines can access the 
lymphatic drainage system for lymph node delivery while protecting cargoes from 
environmental degradation. Once at the lymph nodes, the nanocarriers can deliver their 
cargoes to antigen‐presenting cells (APCs) for immune processing. c) Nanovaccine 
properties can be tuned to efficiently deliver their cargoes for maximum immune 
activation. For example, nanoparticles can be modified to target specific subsets of 
immune cells. They can also be delivered to specific intracellular compartments, where 
receptors for immune pathways can be triggered. 
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1.3 Nanoparticle-Based Cancer Vaccines 
 
1.3.1 Nonspecific Modulation 
 
Some immunomodulatory nanoparticle platforms work to nonspecifically 
boost immune system function. While not strictly considered vaccines, these 
systems do rely on a patient's own tumor as the source of antigenic material and 
work by augmenting immune processes such as antigen processing and antigen 
presentation. This is generally achieved by manipulating the immune system in a 
way that reduces immunosuppression or activates specific immune cell subsets to 
potentiate a response against cancer cells. In some cases, these formulations can 
also be combined with tumor cell killing mechanisms to increase exposure to 
tumor‐associated antigens.  
 
1.3.1.1 Enhancing Physical Proximity of Immune Cells 
An intuitive method for boosting antitumor immune activity is to bring the 
principal immune cells responsible for tumor elimination closer to their target. To 
achieve this, nanoparticles can be decorated with two different antibodies, one to 
target and/or activate immune cells, and another to target the tumor cells. By using 
these bifunctional nanoparticles, nearby immune cells can be targeted to tumors, 
increasing the chance of exposure to released tumor antigens or apoptotic cancer 
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cells while enhancing immune stimulation. In a first example, biodegradable 
poly(lactic acid) nanoparticles were decorated with antibodies against the dendritic 
cell costimulatory marker CD40, as well as an antibody against human epidermal 
growth factor receptor 2 (HER2)/neu, a common tumor antigen overexpressed in 
human breast cancer [68].  The anti‐CD40 antibody was found to both bind and 
activate dendritic cells, inducing a strong proinflammatory immune response that 
could be directed toward neu+ tumors. Intratumoral injection of the nanoparticles 
yielded 100% rejection, while systemic injections resulted in 70% of mice rejecting 
neu+ tumors. Importantly, rechallenge of mice that rejected the primary tumor did 
not lead to any subsequent tumor growth. In another example, polystyrene 
nanoparticles were conjugated with antibodies against HER2/neu and calreticulin, 
a protein that facilitates phagocytosis in APCs [69]. Macrophages treated with these 
multivalent bispecific nano‐bioconjugate engagers were able to better take up 
HER2+ cancer cells and presented tumor‐associated antigens via MHC surface 
complexes. Intratumoral and intravenous injections of the nanoparticles led to 
higher infiltration of CD8+ T cells and inhibited the growth of HER2‐expressing 
tumors. Upon rechallenge, treated mice rejected HER2+ cancer cells but not 
HER2− cells, demonstrating the specificity of the treatment and the durability of the 
response. Instead of binding APCs to tumor cells, it has also been demonstrated 
that antigen‐specific T cells can be linked to cancer cells in a similar manner 
[70].  Conjugation of nanoparticles with SIY–MHC complexes effectively enabled 
binding to 2C T cells, while the inclusion of anti‐CD19 allowed for crosslinking 
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with CD19+ Raji cancer cells. Shortly after intratumoral injection of the 
nanoparticles, mice were infused with adoptively transferred 2C T cells, which led 
to significant retardation of tumor growth. 
 
1.3.1.2 Reduction of Immunosuppression 
The immunosuppressive tumor microenvironment is a hurdle for most 
anticancer immunotherapy treatments, as effector cells can be rendered ineffective 
by inhibitory proteins or anti‐inflammatory cytokines. For example, a melanoma‐
specific peptide vaccine was found to be effective for early stage melanoma, but it 
failed to demonstrate efficacy at later disease stages due to increased levels of 
immunosuppressive cytokines like tumor growth factor β (TGFβ) in the tumor 
microenvironment [71].  To address this, a liposome–protamine–hyaluronic acid 
nanoparticle was designed to deliver siRNA against TGFβ into tumor cells 
[72].  Injection of the nanoparticles halved the levels of TGFβ in the tumor 
microenvironment while doubling the efficacy of the vaccine. This improvement 
was discovered to be caused by an increase in CD8+ T cells in the late stage tumor 
tissue along with a marked decrease in regulatory T cell levels. Other 
immunosuppressive efforts focus on the expression of signaling proteins on tumor 
tissue that interact with immune cells. Well‐known pathways such as PD1 can be 
intercepted using checkpoint blockades, but systemic administration can have toxic 
side effects, potentially leading to the development of autoimmune diseases and 
pathological inflammation [73].  In one recent work, platelet‐derived 
 
 
 17 
microparticles were used as a carrier for antibodies against programed death‐ligand 
1 (PDL1) [74].  After tumor resection, residual cancer cells can oftentimes start to 
regrow the tumor or be released into circulation. These remaining cells can express 
PDL1 in response to inflammation, making it highly difficult for the immune 
system to destroy them and prevent tumor recurrence. Due to the abundance of 
exposed collagen in wound sites, platelet microparticles were chosen as the delivery 
vehicle for anti‐PDL1 given their inherent targeting ability. Intravenous injection 
of the microparticles immediately after incomplete tumor resections was shown to 
greatly reduce tumor regrowth and metastasis formation in both B16‐F10 
melanoma and triple‐negative 4T1 breast cancer mouse models. Similarly, 
immunotherapy mediated by low dose doxorubicin has been shown to have partial 
efficacy against B‐Raf proto‐oncogene mutant melanoma, but it failed at long‐term 
efficacy likely due to the emergence of the Wnt family member 5a (Wnt5a) protein 
on cancer cells. Wnt5a can induce dendritic cell tolerance and cause fibrosis of 
tumor tissue, as well as prevent T cell infiltration. A lipid–protamine–DNA 
nanoparticle loaded with plasmid DNA encoding for a Wnt5a trap was able to 
transiently reduce Wnt5a levels in the tumor microenvironment and significantly 
boost treatment efficacy using doxorubicin [75].  
 
1.3.1.3 Immune System Activation 
The immune system can be boosted through the introduction of 
immunostimulatory payloads, including pathogen‐associated molecular patterns 
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(PAMPs), costimulatory markers, cytokines, and other signaling proteins. Adjuvant 
administration has been found to be a powerful nonspecific modulator to aid in 
cancer immunotherapy. PAMPs such as single‐stranded DNA, double‐stranded 
RNA, and lipopolysaccharides are recognized by the TLRs found on immune cells 
and help to promote downstream inflammatory responses. Many of these PAMPs, 
such as CpG oligonucleotides (ODNs) recognized by endosomal TLR9, have been 
extensively used as adjuvants in conjunction with a coinjection of proteins or 
peptides to promote specific immune responses [76-80].  Other TLR‐targeted 
PAMPs such as monophosphoryl lipid A (MPLA) [81, 82] and imidazoquinoline 
[83] have been used in nanoparticle formulations as adjuvants, and some PAMPs 
have even been coloaded together to simultaneously engage multiple different 
TLRs [84].  
Cyclic dinucleotides (CDNs), small nucleic acids characteristic of invading 
microbes, are a family of type I interferon (IFN)–producing PAMPs. These CDNs 
are in phase I clinical trials, but they require very high dosages to ensure that 
adequate amounts can get into the cytosol to interact with their stimulator of 
interferon genes (STING) receptor. Encapsulation of CDNs into nanoparticles can 
improve cytosolic delivery and enhance immune responses at lower concentrations. 
In one work, cyclic diguanylate was encapsulated into polyethylene glycol‐
functionalized lipid nanoparticles and used to adjuvant soluble ovalbumin (OVA) 
protein [85].  After vaccination, a significant increase in both CD8+ and CD4+ T 
cells was observed, and T cells restimulated with OVA produced fivefold increases 
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in IFNγ and tumor necrosis factor α (TNFα). Further, a CDN‐adjuvanted B16‐F10 
vaccine formulation induced a sevenfold higher frequency of gp100‐specific 
CD8+ T cells and significantly delayed B16‐F10 tumor growth. CDNs have also 
been incorporated into nanoparticles consisting of cationic poly(β‐amino ester) 
(PBAE), a polymer widely used for cytosolic delivery of DNA [86].  Delivery of 
cyclic diguanylate to THP‐1 cells using a PBAE carrier yielded an equivalent 
amount of IFN regulatory factor 3 activation as free CDN, but at a 100‐fold lower 
dose of adjuvant. When the nanoparticles were given as an intratumoral injection 
along with anti‐PD1 antibodies, complete remission of B16‐F10 tumors was seen 
at an order of magnitude lower CDN dosage than the soluble form. 
The repetitive protein structure of viral capsids self‐assembled into 
nanoparticles can also serve as a PAMP. For example, cowpea mosaic virus is a 
noninfectious agent that self‐assembles into hollow, icosahedral 30 nm virus‐like 
particles, which can have strong antitumor immunotherapeutic activity (Figure 1.2) 
[87, 88].  Inhalation of the virus‐like particles by B16‐F10 tumor–bearing mice 
increased tumor‐infiltrating neutrophils, activated neutrophils in the lung 
microenvironment, and elevated levels of neutrophil‐secreted cytokines. 
Significantly delayed tumor growth was seen after injections of the nanoparticles 
via various routes in multiple different tumor models. In particular, the virus‐like 
particles were able to eliminate primary B16‐F10 tumors in half of mice upon 
intratumoral injection, as well as provide long‐term antitumor immunity as shown 
by rejection of a contralateral B16‐F10 rechallenge. Other virus‐like particles such 
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as the papaya mosaic virus [89],  influenza virus [90],  and tomato yellow leaf curl 
virus [91]  have also shown strong adjuvanting properties that can be taken 
advantage of for immune modulation. 
Cytokines serve a very important role in the adaptive immune system and can 
also be used for potent immune activation. For instance, mast cells can influence 
dendritic cell migration to the lymph nodes and upregulate inflammatory responses 
through the release of granules full of immune mediators like TNF. To mimic this 
Figure 1.2: Virus‐like nanoparticles for in situ anticancer vaccination. a) Schematic 
depicting the synthesis of empty cowpea mosaic virus (eCPMV) nanoparticles and 
their expected mechanism of action for tumor treatment. b,c) When used to treat tumor‐
bearing mice, virus‐like nanoparticles significantly enhanced survival in both a 4T1‐
luc metastatic breast cancer model (b) and an ID8‐Def29/Vegf‐A ovarian cancer model 
(c). Reproduced with permission Copyright 2016, Springer Nature. 
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natural boosting of the immune system, synthetic mast cell granules were 
synthesized by trapping TNF into a nanoparticle matrix of chitosan–heparin 
[92].  Like real mast cell granules, the particles drained to lymph nodes and 
promoted germinal center formation. Due to the modular nature of the 
nanoparticles, TNF could be replaced with interleukin‐12 (IL12) to promote 
polarization of immune cells toward proinflammatory phenotypes, such as IFNγ‐
secreting T cells. Delivery of IL2, a crucial cytokine for T cell survival and 
proliferation, has also been explored as a method to enhance T cell–mediated 
immunotherapy. Hydroxyethyl starch nanocapsules were coupled with IL2 using 
copper‐free click chemistry, and incubation with T cells resulted in a high level of 
uptake and a fourfold increase in division index compared to unmodified 
nanocapsules. It has been shown previously that nanoparticles delivering a 
combination of different classes of immune‐activating adjuvants can promote 
increased therapeutic efficacy [93]. Combinations of cytokines with other 
molecules, such as PAMPs [94]  and costimulatory ligands [95],  have also been 
shown to synergistically activate immune cells. 
 
1.3.1.4 Immune Activation and Immunosuppressive Intervention 
Combination 
Beyond combining different methods of activating immune cells, 
simultaneous use of immunosuppressive intervention and immune activation can 
also yield impressive results. For example, combining IL10 siRNA and CpG ODN 
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into a pathogen‐mimicking nanoparticle resulted in a balanced Th1/Th2 cytokine 
response that improved antitumor efficacy [96]. Immune activating R848 has also 
been delivered to T cells by encapsulation in nanoparticles that were targeted to T 
cells expressing PD1 [97].  To enhance costimulation while reducing 
immunosuppression, dual‐targeted nanoparticles have been developed with both 
agonistic and antagonistic antibodies conjugated onto the same surface. In one case, 
anti‐4‐1BB was attached onto particles to activate the 4‐1BB costimulation 
pathway on CD8+ T cells, while the conjugation of anti‐PDL1 served to block 
PDL1 expressed on the surface of cancer cells [98]. Alternatively, nanoparticles 
decorated with anti‐OX40 and anti‐PD1 were able to target T cells expressing both 
receptors, simultaneously activating them and preventing their anergy [99].  In both 
the cases above, T cells were less inhibited by the immunosuppressive tumor 
microenvironment, leading to enhanced antitumor efficacy in a variety of mouse 
cancer models. 
 
1.3.1.5 Combination with Traditional Anticancer Therapies 
In the examples discussed thus far, it can be understood that the 
immunostimulatory nanoparticle platforms relied on the natural immune processing 
of tumor cells as the source of antigenic material. To facilitate the generation of 
tumor antigens and downstream immune activation, another strategy is to actively 
promote the release of material from tumors while concurrently introducing 
nonspecific immune modulators. For example, administration of the 
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immunotherapeutic potato virus X alone caused a modest decrease in the growth 
rate of B16‐F10 cancer cells, similar to monotherapy with doxorubicin. However, 
coadministration of both the components led to a significant improvement in 
antitumor efficacy [100].  In another work, cytotoxic cationic silica nanoparticles 
were used to induce necrotic cell death while delivering a STING agonist to the 
immune cells in the tumor microenvironment [101].  Finally, “sticky” nanoparticles 
were designed to capture antigens in situ before being phagocytosed by immune 
cells [102].  After administration of anti‐PD1 antibodies, primary tumors were 
irradiated and then injected with the antigen‐capturing nanoparticles. Taking 
advantage of the abscopal effect, protein‐loaded nanoparticles could then travel to 
the lymph nodes to facilitate an adaptive immune response, which led to the 
eventual destruction of a secondary tumor in 20% of mice. 
 
1.3.2 Specific Modulation 
 
The ultimate goal of vaccination is to stimulate the immune system while 
simultaneously guiding a specific response against the desired target. For cancer 
immunotherapy, this target is often a lowly immunogenic antigen that is 
differentially expressed by tumor cells. As a result, an ideal cancer vaccine requires 
delivery of the relevant antigens along with a potent immunological adjuvant, 
which can be used to force the immune system to mount an antitumor response. In 
recent research, nanotechnology has been employed to further improve the efficacy 
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of cancer vaccines using several strategies, including inherent nanoparticle 
adjuvancy, codelivery of antigen and adjuvant, targeted delivery to immune cells, 
enhanced immune cell uptake and cross‐presentation, and cytosolic delivery. 
 
1.3.2.1 Inherent Nanoparticle Adjuvancy 
There is a wide variety of materials and structures that can be made into 
nanoparticles, and one strategy for the formulation of nanovaccines is to carefully 
choose a material that is naturally immunostimulatory. This can help to streamline 
nanoparticle fabrication by reducing the complexity of the final formulation. As an 
example, nanoparticles made of viral capsids naturally activate the immune system, 
largely due to the conservation of repetitive protein structures or the retention of 
nucleic acid‐based PAMPs. These virus‐like particles can engage TLRs in immune 
cells while delivering an antigenic payload. Even very lowly immunogenic tumor–
associated antigens like idiotypic immunoglobulin from B cell lymphomas can 
elicit a strong humoral response when delivered by nanoparticles made of potato 
virus X coat proteins [103].  Other gel‐like nanoparticles can be made by 
crosslinking materials that mimic the structure of PAMPs, such as hydrophobic 
polymers [104], peptides [105, 106],  or DNA [107],  while also encapsulating 
antigens. d‐tetra‐peptide hydrogels in particular show promise as a vaccine 
adjuvant. Nanoformulations made by mixing irradiated tumor cells with a self‐
assembling hydrogel made of the d configuration of naphthylacetic acid‐modified 
 
 
 25 
GFFY peptide were able to significantly protect mice from both E.G7 and 4T1 
tumor challenges [108].  
Immune responses to antigens can also be naturally boosted by carefully 
tuning their release over time. Nanogels are especially adept at this, as protein‐to‐
polymer ratios can be precisely varied to change matrix spacing and cargo release 
rates [109, 110].  Some formulations have shown impressive sustained protein 
release, such as a PBAE layer‐by‐layer microparticle that extended release half‐life 
from 4.9 to 143.9 h [111],  or a hyaluronic acid‐based nanogel that released proteins 
for over one week in rats [112].  Antigen delivery can be further improved by 
modifying nanogels to be retained at the immunization site, promoting sustained 
release of the payload in the presence of immune cells [113].  Polymeric 
nanoparticles can also provide sustained protein release profiles, as in the case of a 
poly(lactic‐co‐glycolic acid) (PLGA)‐based formulation that was shown to release 
OVA protein for over a week [114].  When modified to carry gp100 or B16‐F10 
lysate, the same particles could produce approximately threefold greater T cell 
activation compared to equivalent doses of protein in soluble form, and this resulted 
in superior B16‐F10 tumor suppression. 
 
1.3.2.2 Codelivery of Antigen and Adjuvant 
In general, delivery of antigens alone is not enough to trigger a strong 
immune response, requiring the use of an adjuvant to boost immune activation. For 
example, OVA antigen conjugated to poly(propylene sulfide) nanoparticles showed 
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no anti‐OVA immune response in mice, but high levels of dendritic cell maturation 
and OVA‐specific T cell generation were observed when the same particles were 
delivered along with an administration of CpG, resulting in protection against 
influenza–OVA challenge [115].  Furthermore, vaccines generally work the best 
when the antigen and adjuvant are delivered concurrently to the same APC, which 
can be readily accomplished using nanoparticle‐based systems. This idea was 
shown systematically with a model cancer vaccine consisting of a polymeric 
nanoparticle loaded with an OVA peptide and the TLR7/8 agonist R848 
[116].  Administration of a nanoparticle encapsulating both the payloads resulted 
in higher anti‐OVA IgG production compared to either component in free form, 
one component in free form and the other encapsulated, or both the components 
encapsulated separately. In addition, codelivery of both the components together 
enhanced downstream T cell–mediated lysis of OVA‐expressing cells and elicited 
increased local cytokine production. Many platforms have been designed for the 
codelivery of antigen and adjuvant together, including inter‐bilayer‐crosslinked 
multilamellar vesicles loaded with OVA antigen inside and MPLA interspersed 
throughout their lipid bilayers [117].  Immunization with this formulation led to an 
impressive 28% of CD8+ T cells exhibiting OVA specificity, which was 14 times 
greater than observed when using soluble OVA and MPLA. These specific T cells 
also retained their functionality, as shown by high IFNγ production upon 
restimulation with OVA ex vivo. 
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When vaccinating against a heterogenous target like cancer cells, 
multiepitope vaccine formulations can be employed to prevent immune escape and 
tumor recurrence [20].  Modular vaccine designs, exemplified by recent work 
describing designer nanodisks [118],  can help overcome this barrier. Synthetic 
high‐density lipoprotein nanodisks were mixed with cholesterol‐modified CpG 
ODN for immunogenicity and further functionalized with cysteine‐modified, 
tumor‐specific neoantigens for specificity. Mice immunized with nanodisks 
harboring a combination of three antigens experienced an expansion in their pool 
of antigen‐specific CD8+ and CD4+ T cells when compared to those receiving 
soluble formulations. The multiantigen formulation also showed significantly 
better control of B16‐F10 tumor growth compared to single‐antigen or dual‐antigen 
formulations. Impressively, when mice were vaccinated in combination with anti‐
PD1 and anti‐CTLA4, 90% were cured of their tumor burden. 
 
1.3.2.3 Immune Cell Targeting 
Due to the easy surface functionalization properties of nanoparticles, the 
efficacy and efficiency of nanovaccines can be improved by including an immune 
cell targeting moiety. Vaccine processing mainly takes place in APCs, and thus the 
most common immune cells targeted are dendritic cells and macrophages. A variety 
of surface markers can be targeted, such as the C‐type lectin mannose receptor 
(CD206) by the inclusion of mannose on the nanovaccine surface [71, 119, 120].  In 
one example, the targeting ability of mannose was examined, and it was observed 
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that functionalization could increase particle uptake into bone marrow–derived 
dendritic cells [121].  Strong localized signal of a fluorescently labeled targeted 
nanovaccine was seen in the draining lymph nodes at 24 h, while particles without 
mannose started to lose signal as early as 12 h after injection. Other surface markers 
such as CD11c [122],  scavenger receptor class B type 1 [123],  DEC205 [124, 
125],  and macrophage galactose‐specific C‐type lectin [55]  have also been 
commonly targeted.  
 
1.3.2.4 Efficient Cytosolic Entry 
Traditional cancer vaccines suffer from difficulty in entering the cytosol of 
immune cells. Cytosolic entry can help to facilitate the presentation of antigens by 
MHC‐I and subsequent mobilization of CD8+ effector T cells. In addition, there are 
several maturation pathways and pathogen recognition receptors located in the 
cytosol that can be leveraged to boost the potency of vaccine formulations. As most 
nanoparticles are taken up endosomally, there exist many strategies for facilitating 
endosomal escape. Due to the characteristic acidic environment of the endosomal 
compartment, redox‐responsive nanovaccines can be used to achieve this goal. For 
example, some polymeric nanoparticles can act as proton sponges and induce 
lysosome swelling and rupture when encountering low pH environments [126]. 
Lysosomal rupture–triggered reactive oxygen species have also been shown to 
enhance proteasome activation, which can help to trigger MHC‐I antigen 
presentation [55].  In one case, the common transfection agent, polyethylenimine, 
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was coated onto the surface of antigen‐loaded polymeric nanoparticles, and this 
helped to facilitate cross‐presentation of the loaded antigen after uptake 
[127].  Similar reducible polymeric systems like poly(γ‐glutamic acid) 
nanoparticles [128]  and cationic dextran nanogels [129]  have also shown a similar 
ability for facilitating MHC‐I restriction. Besides endosomal escape, there are other 
ways to enter the cytosol from the endosomal compartment. OVA‐loaded α‐
alumina nanoparticles can engage noncanonical autophagy, where antigens are 
diverted into autophagosomes and the delayed antigen degradation allows for 
increased cross‐presentation [130].  By taking advantage of this process, significant 
levels of OVA‐specific T cells could be induced, enabling mice to completely reject 
established B16‐OVA tumors in vivo. In another strategy, nanoparticles can be 
designed to directly cross cell membranes by incorporating cell penetrating 
peptides onto their surfaces [131-133].  Macropinocytosis of lipid‐coated 
nanovaccines has also been reported [134].   
Cytosolic localization gives delivered antigens access to MHC‐I presentation, 
but it can also be leveraged to enhance immune stimulation. Recent work has shown 
that retinoic acid‐inducible protein 1 ligands and STING ligands may be stronger 
activators of the immune system than traditional TLR‐based adjuvants like CpG 
and MPLA [85, 135].  PC7A synthetic nanoparticles have been used to deliver 
antigen while simultaneously activating the STING pathway (Figure 1.3) [136, 
137].  When loaded with OVA, the nanoformulation induced a threefold increase 
in antigen cross‐presentation due to endosomal disruption by the redox‐responsive 
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PC7A. Once in the cytosol, the PC7A also engaged the STING receptor, resulting 
in higher immune activation compared to poly(I:C) or other polymeric nanoparticle 
groups. The combination of potent STING activation and efficient antigen cross‐
presentation led to significant antitumor efficacy against loaded antigens in B16‐
OVA, B16‐F10, MC38, and TC‐1 mouse tumor models. 
Instead of delivering antigens directly to the cytosol, some recent work has 
also focused on delivery of antigen‐encoding RNA for in situ transcription and 
antigen production [120, 134, 138].  Acid‐dissolvable calcium phosphate 
nanoparticles carrying messenger RNA (mRNA) encoding the tumor‐associated 
Figure 1.3: Synthetic nanoparticles activating the STING pathway for antitumor 
vaccination. a) Schematic depicting an antigen‐loaded synthetic nanocarrier (PC7A) 
and its proposed mechanism of action. b,c) When used to treat tumor‐bearing mice, 
antigen‐loaded PC7A nanoparticles significantly enhanced survival in both a B16‐F10 
melanoma model (b) and an MC38 colon cancer model (c). Reproduced with 
permission. Copyright 2017, Springer Nature. 
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tyrosinase‐related protein 2 (TRP2) could elicit stronger antigen‐specific T cell 
responses and humoral responses against B16‐F10 melanoma compared to peptide 
delivery [120].  In addition, PDL1 siRNA could be delivered to directly 
downregulate PDL1 in dendritic cells to reduce immunosuppression. Cytosolic 
delivery of both the mRNAs was shown to have a potent antitumor effect, 
significantly better than cytosolic delivery of either component alone. This strategy 
of RNA antigen sourcing has also been implemented using a highly modular RNA–
lipoplex platform [134].  RNA‐containing lipoplexes were optimized to target the 
spleen by modifying the charge ratios of the components, and the resulting 
formulation was shown to be taken up into the cytoplasm of dendritic cells and 
macrophages via macropinocytosis. The nanoparticles also induced TLR7‐
triggered IFNα production and IFN‐α/β receptor–dependent activation of APCs. 
Introduction of antigen‐encoding RNA induced generation of functional antigen‐
specific T cells and memory cells, which resulted in potent antitumor efficacy in 
several tumor models. Moving toward clinical translation, three human patients 
with advanced malignant melanoma received five doses of the nanovaccine 
encoding for four tumor antigens. All three patients showed systemic IFNα 
production, along with de novo priming and amplification of T cells against the 
vaccine antigens. 
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1.3.2.5 Artificial Antigen Presentation 
Most cancer vaccines work by manipulating APCs, which can then further 
stimulate antigen‐specific T cells and B cells. Recently, there has been significant 
interest in developing artificial APCs (aAPCs) that are capable of directly 
stimulating effector cells [139].  This strategy was originally developed in order to 
effectively expand T cells ex vivo for adoptive cell therapies such as CAR T cell 
therapy [140].  These aAPCs, which include both live cell–based and synthetic 
micro‐/nanoparticle‐based platforms, mimic professional APCs and can strongly 
activate T cells while avoiding the intensive labor, high cost, and difficulty in 
quality control when using autologous APCs. Similar to their natural counterparts, 
aAPCs require at least two signals to induce T cell activation. The first signal, a 
peptide–MHC complex, binds to its cognate T cell receptor (TCR) and establishes 
antigen specificity. To become fully activated, T cells require a second signal in the 
form of costimulatory molecules such as CD80 and CD86, which engage their 
corresponding receptor on the T cell surface [139]. With these two signals, aAPCs 
have the potential to act as a vaccine‐like platform that can expand antigen‐specific 
T cell populations, but without the use of immunological adjuvants. In addition to 
the minimum two signal requirement, at times a third signal, in the form of soluble 
cytokines, can further enhance the survivability of the activated T cells [141].  
To generate nanoscale aAPCs capable of engaging and activating T cells, 
MHC–Ig along with a costimulatory signal, in the form of CD80 or anti‐CD28, has 
been decorated onto the surface of nanoparticles (Figure 1.4) [142].  When 
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administered subcutaneously, nanoscale aAPCs exhibited greater lymphatic 
drainage compared with microscale aAPCs, which largely remained at the injection 
site. When administered into tumor‐bearing mice that received adoptively 
transferred antigen‐specific T cells, the nanoparticles were able to help significantly 
control tumor growth. It has also been demonstrated that aAPCs can be fashioned 
using magnetic nanomaterials [143].  After incubation with their cognate T cells, 
these magnetic aAPCs helped to induce significant proliferation and could also 
guide the T cells to tumors with the use of a magnetic field. In the future, such a 
platform may be directly used in vivo to promote antitumor activity. Interestingly, 
it has been found that the shape of nanoscale aAPCs can have a significant impact 
on their biological activity [144]. Ellipsoid nanoparticles were fabricated by 
stretching spherical PLGA nanoparticles, followed by conjugation with anti‐CD28 
and MHC–Ig loaded with a gp100 tumor antigen epitope. After intravenous 
injection, it was observed that the ellipsoid particles could induce more antigen‐
specific T cells in circulation compared with their spherical counterparts. Although 
there are currently limited examples of nanoparticulate aAPCs being used in vivo, 
this nanovaccine‐like platform holds significant potential given its ability to help 
bypass the complicated processes of antigen processing and presentation. 
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1.4 Cell Membrane-Coated Nanovaccines 
 
1.4.1 Background 
 
As discussed thus far, nanoparticle technology has the potential to 
significantly alter the landscape of anticancer vaccination, enabling the design of 
Figure 1.4: Quantum dot (QD) nanoparticles for artificial antigen presentation. a) 
Schematic depicting the artificial antigen presenting cell (aAPC) structure, where both 
the signals are attached to the nanoparticle surface using biotin–avidin interactions. b) 
When injected intravenously into B16 tumor–bearing mice that were also adoptively 
transferred with antigen‐specific T cells, the aAPCs were able to significantly control 
tumor growth. Reproduced with permission. Copyright 2014, Elsevier Inc. 
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new nanovaccines with improved efficacy compared with traditional formulations. 
More recently, there has been a noticeable paradigm shift within the field of 
nanomedicine in which a greater emphasis has been placed on biomimetic design 
principles [145-148].  Along these lines, a new cell membrane coating approach 
has emerged in which nanoparticles are cloaked with a layer of cell‐derived 
membrane [149-151].  In contrast to traditional bottom‐up synthetic strategies, top‐
down membrane coating directly leverages naturally occurring biological material 
for the fabrication of multifunctional nanoparticles. Using red blood cells (RBCs) 
as the source of membrane material, it was demonstrated that RBC membrane–
coated nanoparticles gained the ability to avoid immune clearance and circulated 
for extended periods of time (Figure 1.5) [152].  The cell‐mimicking properties of 
these biomimetic nanoparticles result from the transference of the originating cell's 
membrane proteins onto the surface of the nanoparticle substrate [153].  This 
approach for functionalization has proven to be highly generalizable, allowing for 
the delivery of a wide range of cargoes using different types of materials for the 
inner core [154, 155].  The outer membrane layer can also be modified with further 
functionality by facile means, affording additional flexibility to membrane‐coated 
platforms [54, 156]. 
Since the first work on RBC membrane–coated nanoparticles was reported, 
research on cell membrane coatings has expanded in multiple directions. In addition 
to modulating the material composition of the inner core, the membrane can be 
sourced from a plethora of cell types, each resulting in unique formulations with  
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novel properties. For example, platelet membrane–coated nanoparticles exhibit the 
ability to target bacteria and damaged vasculature [157, 158],  while cancer cell 
membrane–coated nanoparticles can homotypically target cancer cells 
[159].  White blood cell membrane, with its various toxin and cytokine receptors, 
has utility for treating sepsis [160].  Other membrane‐coated formulations have also 
been reported using stem cell membrane [161],  endothelial cell membrane 
[162],  and even hybrid membranes generated from multiple cell types [163].  As a 
result of all the complex functionalities that can be incorporated, this approach has 
enabled the resulting biomimetic nanoparticles to excel in nontraditional areas of 
nanomedicine. A major example is detoxification, where membrane‐coated 
particles can act as nanosponges to neutralize toxins by taking advantage of their 
Figure 1.5: Functionalization of nanoparticles with a cell membrane coating. 
Schematic depicting the fabrication of red blood cell (RBC) membrane–coated 
nanoparticles. RBC vesicles are obtained by hypotonic treatment, followed by coating 
onto polymeric nanoparticle cores using extrusion. The resulting membrane‐coated 
nanoparticle exhibits a characteristic core–shell structure. Reproduced with 
permission. Copyright 2011, National Academy of Sciences. 
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interactions with cell membranes [164-166]. By neutralizing these toxins and 
preventing them from attacking healthy cells, these nanoscale decoys have utility 
for the treatment of bacterial infections, animal envenoming, and even exposure to 
chemical warfare agents. The ability of cell membrane–coated nanoparticles to bind 
and present multiple antigens, combined with the flexibility of choosing various 
core materials, has also made them suitable for vaccine design [23, 24].  
 
1.4.2 Cell Membrane-Coated Nanoparticles for Antibacterial 
Vaccination 
 
Overall, vaccines represent one of the most efficient methods of reducing the 
global health burden posed by bacterial infections [167].  Toxoid vaccination 
represents an effective means of disarming bacteria of their virulent proteins, 
making it harder for the pathogens to colonize their host. This strategy is currently 
used in the clinic to vaccinate against tetanus and diphtheria [168].  In order to make 
bacterial toxins safe for administration, they are generally inactivated with harsh 
chemical or heat treatments that can damage antigenicity and reduce vaccination 
efficacy. By contrast, RBC nanosponges have demonstrated the ability to naturally 
detain and neutralize bacterial toxins when the two are mixed together, forming 
what are referred to as nanotoxoids [167, 169].  Using methicillin‐
resistant  Staphylococcus aureus (MRSA) and its major virulence factor α‐
hemolysin as a model system, the corresponding nanotoxoid was able to generate 
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significant antitoxin titers, improving overall antibacterial immunity compared to a 
heat‐denatured toxoid formulation [170].  While the control toxoid required 60 min 
of high heat exposure to achieve an acceptable safety profile, the nanotoxoid 
demonstrated excellent safety on a number of cell types at the outset. In animal 
models of both systemic and skin toxin burden, nanotoxoid vaccination on a prime 
with two boosts schedule resulted in almost complete protection. A later study also 
demonstrated the efficacy of this approach against live MRSA infection [171].  
As the mechanism of toxin binding to membrane‐coated nanoparticles relies 
on function rather than the specific structure of the toxin, the nanotoxoid platform 
can be easily generalized. To generate a multiantigenic nanotoxoid, RBC 
nanosponges were mixed with a crude hemolytic protein fraction isolated from 
MRSA culture (Figure 1.6) [172].  It was confirmed that the nanotoxoids contained 
several toxins on their surface, including α‐hemolysin, γ‐hemolysin, and Panton–
Valentine leukocidin. Further, the nanotoxoids were found to be completely safe, 
whereas intense heat treatment of the hemolytic protein fraction could not 
completely abrogate its toxicity. When used as a vaccine, the multivalent 
nanotoxoids were capable of generating antibody titers against all of the 
aforementioned toxins, which helped to reduce bacterial burden upon live MRSA 
challenge. In addition to the nanotoxoid approach, another method of generating 
multiantigenic vaccines is to directly employ bacteria‐derived membrane. Outer 
membrane vesicles (OMVs) are secreted from bacteria and are important in  
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pathogenesis as well as cell‐to‐cell signaling [173].  Some vaccines employing 
OMVs as the antigenic material have already been used in the clinic, as is the case 
with a formulation against meningococcal infection [174].  OMVs are attractive for 
use as antibacterial vaccines because they often share a similar biochemical 
membrane profile with their parent cell [175].  The utility of OMVs can be further 
improved by coating the material around a nanoparticulate core. In one 
instance, Escherichia coli OMVs were coated onto small gold nanoparticles, which 
Figure 1.6: Membrane‐coated nanoparticles for antibacterial vaccination. a) Schematic 
depicting the nanotoxoid concept, which can be used to develop vaccines against 
bacteria‐secreted toxins. b) Vaccination using multiantigenic nanotoxoids fabricated 
with a hemolytic secreted protein (hSP) fraction from methicillin‐
resistant Staphylococcus aureus (MRSA) significantly inhibited lesion formation 
caused by subcutaneous MRSA challenge, leading to decreased bacteria counts. 
Reproduced with permission. Copyright 2017, Wiley‐VCH. 
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provided increased stability and size control compared with free OMVs [176].  Due 
to the ability to finely control their size, the membrane‐coated particles efficiently 
localized to the lymph nodes, leading to strong and durable immune activation. 
 
1.4.3 Cell Membrane-Coated Nanoparticles for Anticancer 
Vaccination 
 
As a whole, antibacterial vaccines have been extremely successful in 
reducing mortality rates related to infection. Unfortunately, the same level of 
clinical success has not been achieved for formulations against cancer. Recently, 
the extension of cell membrane–coated nanoparticles to anticancer vaccination has 
become an active area of research. In one example, an RBC membrane–based 
nanocarrier was designed to deliver a hgp100 tumor antigen peptide and the 
adjuvant MPLA [177].  The platform was further modified with mannose on the 
surface to better target dendritic cells, and this led to enhanced localization to the 
draining lymph nodes. Both prophylactic and therapeutic efficacy were 
demonstrated in a B16‐F10 subcutaneous tumor model, resulting in a slowing of 
tumor growth and a reduction in metastasis. 
Since cancer cell membranes contain a plethora of autologous tumor 
antigens, utilizing the purified membrane of cancer cells as the antigenic material 
can be an effective approach in the design of nanoparticulate anticancer vaccines. 
This was initially demonstrated using B16‐F10 melanoma membrane–coated 
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nanoparticles incorporated with MPLA [159].  The formulation significantly 
increased the maturation of bone marrow–derived dendritic cells and enhanced the 
stimulation of antigen‐specific T cells. More recently, an in‐depth set of studies was 
conducted using a platform in which cancer cell membrane was coated around CpG 
ODN–loaded polymer cores (Figure 1.7) [178].  CpG ODN 1826, a potent TLR9 
agonist in mice, was encapsulated into PLGA cores through a double emulsion 
process, and B16‐F10 membrane was coated onto the adjuvant‐loaded cores by bath 
sonication. When the formulation was administered subcutaneously into mice, 
increased maturation of dendritic cells in the draining lymph nodes was observed, 
as indicated by the upregulation of protein markers such as CD40, CD80, CD86, 
and MHC‐II, when compared to various controls. Notably, CpG encapsulated in 
nanoparticulate form was able to activate the immune system significantly better 
than free CpG, likely due to the preferential cellular uptake of the nanoparticles 
[179-182].  Additionally, it should be noted that TLR9 is located within the 
endosomal compartment, which highlights the power of leveraging the inherent 
properties of nanoparticles to purposefully manipulate immune responses. Mice 
vaccinated with the nanovaccine were able to generate antigen‐specific CD8+ T 
cells against gp100 and TRP2, both of which are melanoma‐associated antigens 
[183].  When immunized mice were challenged with B16‐F10 cancer cells, 86% of 
the mice exhibited no tumor growth, even after 150 days. In a therapeutic setting, 
it was demonstrated that the nanoformulation, along with a cocktail of anti‐PD1 
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and anti‐CTLA4 checkpoint inhibitors, was able to extend the survival of the tumor‐
bearing mice compared to either treatment alone. 
Building upon the concept of using cancer cell membrane–coated 
nanoparticles for antitumor vaccination, various strategies have been employed to 
augment immune responses. For example, mannose was introduced to bestow  
Figure 1.7: Membrane‐coated nanoparticles for anticancer vaccination. a) Schematic 
depicting the fabrication of adjuvant‐loaded cancer cell membrane–coated 
nanoparticles (CpG–CCNPs) and their proposed mechanism of action. b,c) When 
combined with a cocktail of checkpoint blockades (anti‐CTLA4 and anti‐PD1), 
treatment of established B16‐F10 melanoma with the CpG–CCNP nanovaccine resulted 
in significantly slowed tumor growth (b) and improved survival (c). Reproduced with 
permission. Copyright 2017, Wiley‐VCH. 
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immune cell–targeting properties, helping to enhance uptake by dendritic cells and 
subsequently promoting their maturation [184].  As a result of this additional 
functionality, the targeted nanovaccine was able to offer better protection for 
vaccinated mice. It was claimed that this triple combination of an adjuvant, cancer 
cell membrane antigens, and a targeting ligand could work together to generate a 
robust anticancer immune response similar to levels generated against bacterial  
infections. In another example, immune stimulation was enhanced via the 
concurrent delivery of multiple adjuvants in an artificial cancer cell membrane–
coated nanoparticle [185]. CpG‐encapsulated calcium phosphate cores were 
fabricated by a water‐in‐oil microemulsion process and then coated with a 
membrane‐mimicking liposome layer. Then, OVA‐expressing B16‐F10 cancer cell 
membrane proteins were purified by dialyzing the membrane against a detergent 
solution. The membrane proteins, along with the danger‐associated molecular 
pattern Hsp70, were incorporated onto the nanoparticle surface to create the final 
formulation. This dual‐adjuvant formulation was able to significantly upregulate 
maturation markers such as CD80, CD86, and MHC‐II, and treated mice had fewer 
lung metastasis compared to formulations with just the CpG adjuvant. In all, the 
works described in this section demonstrate that cell membrane–coated 
nanoparticles have significant potential to be used as nanovaccines. Armed with the 
versatility to easily modulate both the adjuvant and the cancer membrane material, 
which can eventually be derived from a patient's own tumor, this platform may 
ultimately pave the way for potent, personalized anticancer vaccine therapies. 
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1.5 Conclusion 
 
In this review, we have discussed the progress of using nanotechnology 
toward the design of cancer vaccines. In theory, vaccination represents an attractive 
option for cancer therapy, but in practice there are many challenges that need to be 
overcome in order for such platforms to achieve widespread clinical adoption. 
Generally, it is highly difficult for the immune system to generate a potent response 
against established tumors, which can employ various means to lower their 
immunogenicity over time. With the help of nanoscale delivery vehicles, 
researchers are exploring the design of novel vaccine formulations that can elicit 
immune responses capable of overcoming tumor immunosuppression. Nanocarriers 
offer many advantages, including the effective localization of payloads to the 
desired immune cell populations, loading of multiple cargoes into a single 
nanoparticle, and prolonged release characteristics. 
More recently, a novel type of biomimetic platform, the cell membrane–
coated nanoparticle, has emerged as a strong candidate to drive the further 
improvement of nanovaccine platforms. Membrane coating presents a facile means 
of introducing multiple functionalities onto the same nanoparticle without the need 
for complicated synthetic techniques. Regarding anticancer vaccination, the use of 
cancer cell membrane as the coating material offers an approach for creating 
vaccine formulations rich in tumor antigens. Combined with a nanoparticulate core 
carrying potent immune stimulators and the ability to easily target the resulting 
 
 
 45 
nanoparticles to antigen presenting cells, cancer cell membrane–coated 
nanoparticles can achieve strong inhibition of tumor growth. These 
nanoformulations may be further improved through the continued optimization of 
adjuvant and membrane antigen combinations. Methods can also be developed for 
obtaining membrane material from the resected tumors of patients, enabling the 
facile fabrication of personalized vaccines. 
Looking toward clinical translation, a main challenge will be scaling up 
nanoparticle production in an efficient and cost‐effective manner. 
Nanoformulations will avoid many expenses required for live‐cell vaccines, but 
there will likely need to be a substantial investment of time and resources to adapt 
current lab‐scale manufacturing procedures to high‐throughput workflows capable 
of production at the scale necessary for human patients. These workflows will also 
need to align with good manufacturing practices to meet quality requirements for 
regulatory approval. Finally, significant work will also need to be done on 
evaluating the synergy between vaccines and other types of cancer therapies. By 
simultaneously tackling the challenge of cancer treatment on multiple fronts, it may 
one day be possible to eliminate tumors altogether, regardless of their underlying 
characteristics. 
Chapter 1, in full, is a reprint of the material as it appears in Advanced 
Biosystems, 2019, Ashley Kroll, Yao Jiang, Jiarong Zhou, Maya Holay, Ronnie 
Fang and Liangfang Zhang. The dissertation author was the primary author of this 
paper. 
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2.1 Introduction 
 
Recent successes in the field of immunotherapy have provided convincing 
evidence that, if properly stimulated, the immune system is capable of successfully 
battling a variety of cancer types [1-3]. Despite this fact, an effective anticancer 
vaccine that is widely applicable and facile to administer, while highly sought after, 
has continued to remain elusive [4, 5]. Fundamentally, the challenge lies in the need 
to generate potent and specific immune responses that enable the body to 
successfully distinguish between healthy and diseased tissue [6]. By the time a 
neoplastic growth reaches the malignant stage, the most immunogenic tumor‐
specific antigens have generally been eliminated via negative selection [7, 8]. Some 
promising strategies under clinical investigation have focused on common tumor‐
associated antigens, which are dysregulated wild‐type proteins [9, 10]. However, 
the applicability of such single‐antigen approaches is dependent on tumor 
phenotype, and they may also be subject to some of the same limitations facing 
targeted monotherapies as tumors evolve mechanisms of escape [11, 12]. On the 
other end of the spectrum, whole cell vaccine preparations are capable of delivering 
a wide range of autologous antigens [13, 14], but they have traditionally been 
ineffective. This may be a result of significant interference from a surplus of 
nontumor‐related antigenic material [15] or difficulties in direct administration, 
which have necessitated more complex cell‐based strategies [14, 16, 17]. 
Additionally, the immunosuppressive microenvironment of established tumors is 
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often hard to break [18, 19], leading to suboptimal efficacy despite effective 
training of the immune system. 
Advances in genomics have enabled the elucidation of individual cancer 
mutanomes, which can be leveraged to identify multiple vaccine epitopes on a 
personalized level [20, 21]. Other studies have demonstrated that high mutational 
burden can lead to neoantigen targets that are recognized by the immune system, 
and this correlates with clinical response to checkpoint blockade therapies [22, 23]. 
While personalized epitope identification and vaccine manufacture may currently 
not be practical at large‐scale, these findings confirm that, despite the challenges 
facing whole cell formulations, there is a wealth of relevant antigens to be found in 
autologous tumor material. Applying the principles of biomimetic nanotechnology 
[24-26], we explored the presentation of cancer‐derived membrane material in a 
context that could enable potent, multiantigenic immune responses for anticancer 
vaccine design (Figure 2.1). It was demonstrated that nanoparticulate delivery of 
the membrane, along with an immunostimulatory adjuvant, could facilitate 
enhanced antigen presentation, leading to the activation of tumor‐specific cellular 
responses. Further, when used in conjunction with checkpoint blockade therapy to 
help break tumor immunosuppression [27-29], the nanovaccine formulation was 
able to achieve significant control of tumor growth in a therapeutic setting.  
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2.2 Experimental Methods 
 
2.2.1 B16-F10 Murine Melanoma Cell Culture and Membrane 
Derivation 
 
B16‐F10 mouse melanoma cells (CRL‐6475; American Type Culture 
Collection) were cultured at 37 °C with 5% CO2 in T175 tissue culture flasks 
Figure 2.1: Schematic of CpG‐CCNPs for anticancer vaccination. Membrane derived 
from cancer cells (purple), along with the associated tumor antigens (small colored 
spheres), is coated onto adjuvant‐loaded nanoparticle cores (CpG‐NPs) to yield a 
nanoparticulate anticancer vaccine (CpG‐CCNPs). Upon delivery to antigen presenting 
cells (blue), the vaccine formulation enables activation of T cells (tan) with multiple 
specificities. After detecting the antigens present on the tumor, the T cells are capable 
of initiating cancer cell death (gray). 
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(Becton Dickinson) with Dulbecco's Modified Eagle Medium (DMEM; Mediatech) 
supplemented with 10% bovine growth serum (Hyclone) and 1% penicillin‐
streptomycin (Gibco). At 80–90% confluency, ≈16–18 million cells per flask were 
collected in phosphate buffered saline (PBS; Mediatech) by scraping, pelleted at 
700 × g for 7 min in a Sorvall Legend Micro21R centrifuge, then resuspended in a 
50:50 solution of cryopreservation medium (Hyclone) and complete DMEM. Cell 
aliquots were stored at −20 °C before use. To derive membrane, cells were first 
washed in a starting buffer containing 30 × 10−3 m Tris‐HCl pH 7.0 (Quality 
Biological) with 0.0759 m sucrose (Sigma‐Aldrich) and 0.225 m D‐mannitol 
(Sigma‐Aldrich), then mechanically disrupted in the presence of phosphatase 
inhibitor and protease inhibitor cocktails (Sigma‐Aldrich) using a Kinematica 
Polytron PT 10/35 probe homogenizer at 70% power for 15 passes. Membrane was 
separated from the resulting homogenate by differential centrifugation using a 
Beckman Coulter Optima L‐90K Ultracentrifuge. Homogenate was pelleted at 10 
000 × g for 25 min, and the supernatant was then pelleted at 150 000 × g for 35 min. 
The resulting pellet of cell membrane was washed in 0.2 × 
10−3 m ethylenediaminetetraacetic acid (EDTA; USB Corporation) in DNase 
free/RNase free water (Invitrogen) and stored in the same solution at −20 °C until 
use. Total membrane protein content was quantified by a BCA protein assay kit 
(Pierce). 
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2.2.2 Cancer Cell Membrane-Coated Nanoparticle Preparation and 
Characterization 
 
 Polymeric cores were prepared using 0.18 dL g−1 carboxyl‐terminated 
50:50 poly(lactic‐co‐glycolic) acid (PLGA; LACTEL Absorbable Polymers) using 
a double emulsion process. PLGA was dissolved in dichloromethane at a 
concentration of 50 mg mL−1. 500 µL of polymer was added to 100 µL of 200 × 
10−3 m Tris‐HCl pH 8 and sonicated using a Fisher Scientific 150E Sonic 
Dismembrator at 70% power pulsed (2 s on/1 s off) for 1 min. An outer aqueous 
phase consisting of 5 mL of 10 × 10−3 m Tris‐HCl pH 8 was added to the polymer 
solution and sonicated at the same setting for 2 min. The emulsion was then added 
to 10 mL of 10 × 10−3 m Tris‐HCl pH 8 and magnetically stirred at 700 × g for 2.5 
h. After stirring, the particles were pelleted at 21 100 × g for 8 min, and washed 
twice in 10 × 10−3 m Tris‐HCl pH 8. Adjuvant‐loaded polymeric cores (CpG‐NPs) 
were made by including CpG oligodeoxynucleotide 1826 (CpG), synthesized using 
the sequence 5′‐TCCATGACGTTCCTGACGTT‐3 with all phosphorothioate 
bonds (Integrated DNA Technologies), at 500 × 10−6 m to the inner phase of the 
double emulsion during nanoparticle synthesis. To optimize the loading, CpG‐NPs 
were made with CpG inputs of 250, 500, 1000, and 2000 pmol per 1 mg of PLGA. 
Each formulation was lyophilized overnight, then resuspended in 1 mL of acetone. 
PLGA was precipitated and pelleted with the addition of 1 mL water followed by 
centrifugation at 21 100 × g for 20 min. CpG concentration of the supernatants were 
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measured using a Quant‐iT Oligreen ssDNA quantification kit (Invitrogen) 
according to manufacturer's instructions. Further studies employed an initial input 
of 1000 pmol CpG per 1 mg of PLGA. 
B16‐F10 cancer cell membrane‐coated CpG‐NPs (CpG‐CCNPs) were made 
by pelleting the CpG‐NP cores and resuspending them in solution containing B16‐
F10 cell membrane. The mixture was sonicated in a 1.5 mL disposable sizing 
cuvette (Brandtech) using a Fisher Scientific FS30D bath sonicator at a frequency 
of 42 kHz and a power of 100 W for 2 min. The nanoparticles were washed twice 
in 10 × 10−3 m Tris‐HCl pH 8, and resuspended to a concentration of 25 mg 
polymer per 1 mL of solution in 5 × 10−3 m Tris‐HCl pH 7.5 and 0.2 × 
10−3 m EDTA in DNase free/RNase free water for in vitro studies or in 10% sucrose 
with the same buffer concentrations for in vivo studies. If not used immediately, 
particles were stored at −20 °C. In the study, CpG‐CCNPs were fabricated with 100 
µg of membrane protein per 1 mg of PLGA. Size and surface zeta potential of 
CCNPs were determined through DLS measurements using a Malvern ZEN 3600 
Zetasizer. To test the stability of CCNPs in 10% sucrose solution, particles were 
stored at 4 °C for 2 weeks with size measured by DLS every other day. The 
morphology of CCNPs was examined by transmission electron microscopy using a 
Zeiss Libra 120 PLUS EF‐TEM. Samples were resuspended in 10 × 10−3 m Tris‐
HCl pH 8, deposited onto a glow discharged carbon‐coated 400 square mesh copper 
grid (Electron Microscopy Sciences), and negatively stained with 1 wt% uranyl 
acetate (Electron Microscopy Sciences). 
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2.2.3 Membrane Antigen Retention 
 
Identification of characteristic B16‐F10 tumor antigens was completed via 
western blotting. B16‐F10 whole cells were collected from culture by scraping, 
lysed using 0.2% Triton X‐100 (Sigma‐Aldrich) in water, and sonicated. B16‐F10 
lysed cells, B16‐F10 membrane, and CpG‐CCNPs were analyzed for protein 
content using a BCA assay, then each diluted to 0.2 mg mL−1 in water. Each sample 
was then mixed with NuPAGE 4 × lithium dodecyl sulfate sample loading buffer 
(Novex) and heated for 10 min at 70 °C. 25 µL of each sample was loaded into 12‐
well Bolt 4–12% Bis‐Tris gels (Invitrogen) and run at 165 V for 45 min in 3‐(N‐
morpholino)propanesulfonic acid running buffer (Novex). Proteins were 
transferred to 0.45 µm nitrocellulose membrane (Pierce) in Bolt transfer buffer 
(Novex) at 10 V for 60 min. After blocking with 5% milk (Genesee Scientific) in 
PBS with 0.05% Tween 20 (National Scientific), blots were immunostained with 
mouse antimouse gp100 (EP4863(2); Abcam), rabbit antimouse TRP2 (E‐10; Santa 
Cruz Biotechnology), or mouse antimouse MART1 (A103; Santa Cruz 
Biotechnology). The appropriate horseradish peroxidase‐conjugated secondary 
(Biolegend) was used for secondary staining. Membranes were developed with 
ECL western blotting substrate (Pierce) in an ImageWorks Mini‐Medical/90 
Developer. 
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2.2.4 In Vitro Uptake and Activity 
 
All animal studies were designed and proceeded in compliance to the 
University of California, San Diego Institutional Animal Care and Use Committee. 
Female C57BL/6NHsd mice were obtained at 6–10 weeks old from Envigo Harlan. 
BMDC culture was adapted from a previously published protocol [25]. Healthy 
mice were euthanized using carbon dioxide asphyxiation followed by cervical 
dislocation. Both femurs were dissected, cleaned in 70% ethanol, and cut on both 
ends. Bone marrow was then flushed out of the bone with a 1 mL sterile syringe 
using warm BMDC basal media consisting of 500 mL Isocove's Modification of 
DMEM with 2 × 10−3 m L‐Glutamine and 25 × 10−3 m 4‐(2‐hydroxyethyl)‐1‐
piperazineethanesulfonic acid (HEPES) (Mediatech) supplemented with 50 mL 
USDA certified fetal bovine serum (Omega Scientific), 500 µL 55 × 10−3 m β‐
mercaptoethanol (Gibco), 5 mL 200 × 10−3 m L‐Glutamine (Gibco), and 5 mL 
penicillin‐streptomycin. Cells were then pelleted at 700 × g for 5 min, resuspended 
in BMDC growth media, consisting of the basal media further supplemented with 
10 ng mL−1 granulocyte/macrophage‐colony stimulating factor (GM‐CSF; 
Biolegend), to a concentration of 1 × 106 cells mL−1, and plated into petri plates at 
2 × 106 cells per plate. On the third day of culture, 10 mL of BMDC growth media 
was added to each plate. 
To make CpG‐CCNPs with fluorescently labeled polymeric cores, 1,1′‐
dioctadecyl‐3,3,3′,3′‐tetramethylindodicarbocyanine, 4‐chlorobenzenesulfonate 
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salt (DiD, ex/em = 644/663 nm; Biotium) was added to the PLGA solution at 0.1 
wt% of the polymer during nanoparticle synthesis. For the nanoparticle uptake 
study, BMDCs were collected on day 5 using 1 × 10−3 mEDTA in PBS. Cells were 
washed once in PBS, resuspended in BMDC basal media, and plated into 24‐well 
suspension plates. DiD‐labeled CpG‐CCNPs were added at a final concentration of 
1.4 mg mL−1. At each timepoint (0, 15, 30 min, 1, 2, 6, 12, 24 h), media was 
removed, and the cells were detached with trypsin‐EDTA (Gibco). Cells were 
collected, washed once in trypsin‐EDTA, washed twice in PBS, and resuspended 
in 200 µL of 10% phosphate buffered formalin (Fisher). The adjuvant uptake study 
was conducted similarly, instead employing CpG‐CCNPs synthesized with CpG 
containing a 5′ 6‐FAM modification (Integrated DNA Technologies). Free dye‐
labeled CpG was used at an equivalent concentration for comparison. For all 
experiments, after each time point was collected and processed, 1 drop of NucBlue 
Live ReadyProbe Reagent UV stain (Molecular Probes) was added and data were 
collected using a Becton Dickinson FacsCanto‐II flow cytometer. All data were 
analyzed using FlowJo software. 
The activity of delivered CpG was examined using a BMDC cytokine 
release assay. BMDCs were plated on day 6 into 96‐well plates at a concentration 
of 8 × 104 cells mL−1 in BMDC growth media. Dilutions of CpG‐CCNP or free 
CpG were added to the cells. After 2 h of incubation, the cells were washed three 
times with fresh BMDC growth media and cultured for another 2 d. Supernatant 
was then collected and measured for the presence of proinflammatory cytokines 
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using mouse IL‐6 and IL‐12p40 ELISA kits (Biolegend) according to 
manufacturer's instructions. 
Antigen and adjuvant colocalization was visualized by imaging BMDCs 
incubated with dual‐labeled CpG‐CCNPs. B16‐F10 membrane was labeled using 
CF647 succinimidyl ester dye (Biotium) and used to coat CpG‐CCNPs fabricated 
with FAM‐modified CpG. BMDCs were seeded into 8‐well chamber slides at 7.5 
× 104 cells mL−1 and incubated with the nanoparticles for 15 min at 0.7 mg mL−1. 
Cells were then washed three times with PBS, fixed with 10% formalin for 30 min, 
then washed again three times with PBS and mounted onto coverslips using 
VECTASHIELD mounting media with DAPI (Vector Laboratories). Samples were 
imaged on a Deltavision RT Deconvolution Microscope at 60 × magnification. 
 
2.2.5 In Vivo Cellular Localization and Dendritic Cell Activation 
 
To assess in vivo localization, DiD‐labeled CpG‐CCNPs were injected 
subcutaneously into each hock of female C57BL/6NHsd mice. After 24 h, the 
popliteal lymph nodes were collected into 500 µL of dissociation buffer consisting 
of 1 mg mL−1 collagenase D from Clostridium histolyticum (Roche) and 1 mg 
mL−1DNase I grade II, from bovine pancreas (Roche) in Dulbecco's PBS with 
calcium and magnesium (Gibco). Lymph nodes were dissociated manually by 
pipetting and then were stained with fluorescein isothiocyanate (FITC)‐labeled 
antibodies for dendritic cells (antimouse CD11c, N418; Biolegend), macrophages 
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(antimouse F4/80, BM8; Biolegend), T cells (antimouse CD3, 17A2; Biolegend), 
B cells (antimouse CD19, 6D5; Biolegend), and granulocytes (antimouse Ly‐
6G/Ly‐6C, RB6‐8C5; Biolegend) for 30 min. Appropriate dye‐labeled antibody 
isotypes (Biolegend) were used for gating purposes with cells from an untreated 
lymph node. After washing, dead cells were labeled with propidium iodide 
(Biolegend). Data were collected using a Becton Dickinson FACSCanto‐II flow 
cytometer and analyzed using FlowJo software. 
Dendritic cell activation following immunization with CpG‐CCNPs, CpG‐
NPs, CCNPs, or additional controls was determined by testing dendritic cell 
maturation and lymph node cytokine secretion. To test vaccines with antigens and 
adjuvants delivered as separate components, additional controls of CCNP with free 
CpG and B16‐F10 whole lysate with free CpG were also administered. The CCNPs 
with free CpG formulation was made by mixing the two components such that the 
final ratio was 25 mg of PLGA per 3.5 nmol of CpG. Whole cell lysate was prepared 
by three freeze‐thaw cycles at −80 °C for 10 min followed by 10 min at 37 °C. The 
amount of protein used for the formulation was normalized by the amount of 
Na+K+‐ATPase, a characteristic membrane protein, compared with CCNPs as 
determined by immunoblotting. To examine dendritic cell maturation in vivo, 50 
µL of each formulation at 25 mg mL−1 of nanoparticle, or equivalent, was injected 
into the hock. After 24 h, the popliteal lymph nodes of all treated mice were 
collected into 500 µL dissociation buffer and manually dissociated. Cells were 
stained using FITC antimouse CD11c with either Alexa647‐conjugated antimouse 
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CD40 (HM40‐3; Biolegend), CD80 (12‐10A1; Biolegend), CD86 (GL‐1; 
Biolegend), or MHC‐II (M5/114.15.2; Biolegend). Appropriate dye‐labeled 
antibody isotypes (Biolegend) were used for gating purposes with cells from an 
untreated lymph node. After 30 min of incubation at 4 °C, the cells were washed 
and stained with CellTrace Calcein Violet, AM (Molecular Probes) in PBS 
according to manufacturer's instructions. Data were collected using a Becton 
Dickinson FACSCanto‐II flow cytometer and analyzed using FlowJo software. To 
analyze cytokine production, lymph node‐derived single cell suspensions were 
plated with 500 µL of BMDC growth media in 24‐well tissue culture plates. After 
48 h, supernatant was collected and analyzed for cytokine content using IL‐6 and 
IL‐12p40 ELISA kits according to the manufacturer's instructions. 
 
2.2.6 Adoptive T Cell Proliferation and Native T Cell Generation 
 
B6.Cg‐Thy1a/Cy Tg(TcraTcrb)8Rest/J (pmel‐1) transgenic mice were 
obtained from the Jackson Laboratory at 4–6 weeks old. The spleen, popliteal 
lymph node, and inguinal lymph nodes of one pmel‐1 mouse were collected for 
dissociation into single cell suspensions. The red blood cells in the spleen were 
removed using lysis buffer (Biolegend), and all remaining cells were pooled 
together. CD8+ T cells were separated out using CD8a (Ly‐2) microbeads (Miltenyi 
Biotec) on Miltenyi Biotec MACS LS separation columns per manufacturer's 
instructions. After separation, cells were washed in PBS and stained with 
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carboxyfluorescein succinimidyl ester (CFSE; eBiosciences). Cells were then 
diluted to 2.5 × 106 cells mL−1 and 200 µL was transferred to naïve C57BL/6NHsd 
recipients. 2 h postinjection, each mouse was injected with 50 µL of various vaccine 
formulations in both hocks. 4 d after treatment, the spleens were collected and 
dissociated into single cell suspensions. Adoptively transferred T cells were stained 
for using allophycocyanin (APC)‐conjugated antimouse CD8a (53‐6.7; Biolegend) 
and Pacific Blue‐conjugated antimouse CD90.1 (OX‐7; Biolegend). Data were 
collected using a Becton Dickinson FACSCanto‐II flow cytometer and analyzed 
using FlowJo software. CFSE dilution was used to assess the degree of T cell 
proliferation. 
To assess the native generation of antigen‐specific T cells, C57BL/6NHsd 
mice were vaccinated subcutaneously with 50 µL of the different formulations in 
each hock on days 0, 2, and 4. On day 10, spleens were collected and processed 
into single cell suspensions using mechanical dissociation. After lysing the red 
blood cells, 5 × 106 splenocytes were plated into 6‐well suspension plates and 
pulsed with either 1 µg mL−1 of mouse gp100 peptide with sequence 
EGSRNQDWL (Anaspec) or 1 µg mL−1 of TRP2 peptide with sequence 
SVYDFFVWL (Anaspec) in BMDC growth media. After 7 d, cells were collected, 
washed in PBS, and stained with APC‐conjugated antimouse CD8a and either 
phycoerythrin (PE)‐labeled H‐2Db gp100 tetramer (MBL International) or H‐2Kb 
TRP2 tetramer (MBL International). Data were collected using a Becton Dickinson 
FACSCanto‐II flow cytometer and analyzed using FlowJo software. 
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2.2.7 In Vivo Immunity and Therapeutic Efficacy 
 
To study the protection conferred by vaccination, C57BL/6NHsd mice were 
vaccinated with 50 µL of the different formulations at 25 mg mL−1 of PLGA, or 
equivalent, on days 0, 7, and 14. On day 20, the right flank of each mouse was 
shaved and, on day 21, mice were challenged with 2 × 105 B16‐F10 cells 
subcutaneously on the right flank. Tumors were measured every other day and the 
experimental endpoint was defined as either death or tumor size greater than 200 
mm2. 
To study the antitumor therapeutic effect, C57BL/6NHsd mice were first 
challenged on the right flank with 5 × 104 B16‐F10 cells on day 0. On days 1, 2, 4, 
and 7, mice were vaccinated subcutaneously in the same flank with 200 µL of the 
nanoparticulate formulations. The subcutaneous route was chosen in this case to 
accommodate the larger dosage that was employed. The checkpoint blockade 
cocktail, consisting of 100 µg anti‐CTLA4 (9H10; BioXCell) and 200 µg anti‐PD1 
(RMP1‐14; BioXCell) was administered intraperitoneally on the same days. 
Tumors were measured every other day and the experimental endpoint was defined 
as either death or tumor size greater than 200 mm2. 
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2.3 Results and Discussion 
 
CpG oligodeoxynucleotide 1826 (CpG), a nucleic acid‐based 
immunological adjuvant known to trigger the maturation of antigen presenting 
cells, was encapsulated into biodegradable poly(lactic‐co‐glycolic acid) (PLGA) 
nanoparticle cores via a double emulsion process (Figure 2.2a). The amount of CpG 
that could be loaded started saturating at an initial input of 1 nmol per 1 mg of 
PLGA, and ≈100 pmol of the adjuvant could be loaded at this ratio. To introduce 
tumor antigen material, the membrane derived from B16‐F10 mouse melanoma 
cells was coated onto CpG‐loaded PLGA cores (CpG‐NPs). The process used for 
coating did not significantly alter the amount of adjuvant within the polymeric 
cores. Dynamic light scattering (DLS) measurements showed an increase in 
nanoparticle size after coating, and the zeta potential of the adjuvant‐loaded, cancer 
cell membrane‐coated nanoparticles (CpG‐CCNPs) increased to approximately that 
of pure membrane (Figure 2.2b,c). Successful coating was confirmed by 
transmission electron microscopy (TEM), which revealed a characteristic core–
shell structure (Figure 2.2d). Over time, the CpG‐CCNPs stayed stable in solution 
(Figure 2.2e). Importantly, the presence of known membrane‐bound tumor‐
associated antigens [30], including MART1, TRP2, and gp100, was confirmed by 
western blotting (Figure 2.2f). When normalized by total protein amount, 
significant antigen enrichment was observed on the derived membrane and CpG‐
CCNPs when compared with whole cell lysate.  
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To study the interaction of the nanoformulation with antigen presenting 
cells, bone marrow‐derived dendritic cells (BMDCs) were employed. When 
incubated with dye‐labeled CpG‐CCNPs, quick uptake was observed until 
saturation was achieved at ≈6 h (Figure 2.3a). CpG is known to activate 
proinflammatory responses in antigen presenting cells [31], which is necessary for 
generating potent antitumor immunity. Using a fluorescently tagged CpG, the 
Figure 2.2: Preparation and characterization of CpG‐CCNPs. a) CpG encapsulation 
into PLGA cores with increasing inputs, normalized by polymer weight (n = 3, mean ± 
SD). b) Size of CpG‐NPs, B16‐F10 membrane vesicles, and CpG‐CCNPs (n = 3; mean 
± SD). c) Surface zeta potential of CpG‐NPs, B16‐F10 membrane vesicles, and CpG‐
CCNPs (n = 3; mean ± SD). d) TEM image of CpG‐CCNPs negatively stained with 
uranyl acetate. Scale bar = 100 nm. e) Size stability over time of CpG‐CCNPs stored in 
10% sucrose (n = 3; mean ± SD). f) Western blots for known melanoma‐associated 
antigens MART1, TRP2, and gp100 on B16‐F10 cells, B16‐F10 membrane, and CpG‐
CCNPs. 
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adjuvant was shown to much more readily be internalized by BMDCs when 
encapsulated within the membrane‐coated nanoparticles, which are in the ideal size 
range for endocytosis [32, 33] (Figure 2.3b). To test the implications of this 
enhanced internalization and confirm the integrity of CpG after encapsulation, the 
biological activity of CpG in free form versus nanoparticulate form was assessed 
(Figure 2.3c,d). Secretion of two representative proinflammatory cytokines, 
interleukin‐6 (IL‐6) and IL‐12, was significantly enhanced for the CpG‐CCNP 
formulation, which was approximately an order of magnitude more 
immunostimulatory than free CpG. This effect is likely due to the fact that 
nanoparticulate CpG more readily localizes to the endosomal compartment during 
uptake, where it can engage its endosomal recognition site on toll‐like receptor 9 
(TLR‐9) [34]. It should be noted that CCNPs without adjuvant induced 
significantly less cytokine secretion when incubated with BMDCs at equivalent 
nanoparticle concentrations. While the CpG employed in the studies here was 
murine‐specific, other variants could easily be substituted to promote immunity in 
humans [35]. Further, the integrity of the nanoparticle structure was assessed by 
fluorescent imaging using dye‐labeled CpG and membrane protein, and significant 
colocalization of the two signals confirmed the ability of the CpG‐CCNPs to co‐
deliver both adjuvant and antigen to the same BMDC (Figure 2.3e). Upon in vivo 
 administration subcutaneously via the hock, the nanoformulation could easily be 
detected at the draining lymph node after 1 h, with some appearing at an adjacent 
node after 24 h. Little signal was observed at the spleen given its considerable 
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distance from the injection site. Within the draining lymph node, antigen presenting 
cells such as dendritic cells and macrophages exhibited the highest percentage of 
nanoparticle uptake; B cells and granulocytes also displayed some uptake, while 
the limited amount of signal observed for T cells was likely the result of nonspecific 
interactions with the nanoformulation (Figure 2.3f). 
Figure 2.3: Delivery of antigen and adjuvant to immune cells. a) Uptake kinetics of 
dye‐labeled CpG‐CCNPs by BMDCs (n = 3; mean ± SD). b) Uptake kinetics of dye‐
conjugated CpG in free form or within CpG‐CCNPs by BMDCs (n = 3; mean ± SD). 
c,d) Secretion of the proinflammatory cytokines IL‐6 (c) and IL‐12p40 (d) by BMDCs 
when incubated with either free CpG or CpG‐CCNPs (n = 3; mean ± SD). e) Confocal 
microscopy colocalization of CpG and membrane proteins upon uptake of dual‐labeled 
CpG‐CCNPs by a BMDC. Green = CpG, red = membrane, blue = cell nucleus; scale 
bar = 10 µm. f) Uptake of dye‐labeled CpG‐CCNPs by different immune cell subsets 
in the draining lymph node after in vivo administration (n = 6; mean ± SD). 
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The effect of the nanoformulation on BMDC maturation in vitro was studied 
by looking at the upregulated expression of costimulatory markers CD40, CD80, 
and CD86, as well as MHC‐II. Consistent with the fact that the dendritic cell 
maturation process is largely driven by the detection of pathogen‐associated 
molecular patterns such as CpG, it was observed that both CpG‐CCNPs and CpG‐
NPs without any antigen were equally potent. Without CpG, the antigen‐only 
CCNP formulation exhibited significantly decreased activity. A similar pattern was  
seen when assessing the secretion of IL‐6 and IL‐12 by the BMDCs. When 
administered in vivo, the CpG‐CCNP and CpG‐NP formulations were likewise able 
to induce significant dendritic cell maturation at the draining lymph node after 24 
h (Figure 2.4a–d). They also outperformed additional controls, including CCNPs 
with free CpG and whole cell lysate with free CpG, highlighting the advantage of 
nanoparticulate formulations. The level of cytokine secretion at the draining lymph 
node was shown to be mostly dependent on the presence of CpG, with all 
adjuvanted formulations performing similarly (Figure 2.4e,f). This effect was 
localized, as analysis of cytokine levels in the serum did not yield anything 
significantly above baseline.  
To confirm the utility of the CpG‐CCNP formulation for antitumor 
vaccination, its ability to elicit antigen‐specific immune responses was verified 
using T cell‐based assays. First, pmel‐1 CD8+ T cells, which specifically recognize 
a gp100 epitope, were adoptively transferred to recipient mice, which were 
subsequently vaccinated with the various formulations (Figure 2.5a). Treatment   
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with CpG‐CCNPs resulted in the highest degree of pmel‐1 T cell proliferation, 
indicating that the formulation was able to effectively deliver the gp100 antigen for  
presentation under an immunostimulatory context. Additionally, after a set of 
vaccinations in naïve mice, the CpG‐CCNPs were able to promote the native 
Figure 2.4: Characterization of in vivo dendritic cell maturation. Analysis of dendritic 
cell maturation markers a) CD40, b) CD80, c) CD86, and d) MHC‐II in the draining 
lymph nodes after administration with CpG‐CCNPs and various control formulations, 
including whole cell lysate with free CpG (WC + fCpG), CCNPs with free CpG (CCNP 
+ fCpG), CCNPs, CpG‐NPs, and blank solution (n = 4; mean ± SD). e,f) Concentration 
of proinflammatory cytokines e) IL‐6 and f) IL‐12p40 secreted by immune cells isolated 
from the draining lymph nodes after vaccination with CpG‐CCNPs or various control 
formulations (n = 4; mean ± SEM). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 
0.0001 (compared to CpG‐CCNP); one‐way ANOVA. 
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generation of T cells with multiple tumor antigen specificities (Figure 2.5b,c). T 
cells specific for both gp100 and TRP2 could be isolated and expanded from mice 
vaccinated with the CpG‐CCNPs. Further, when cultured ex vivo, immune cell 
preparations from mice vaccinated with the formulation showed significantly 
enhanced production of IFNγ and IL‐2 when stimulated with a gp100 peptide, a 
TRP2 peptide, or whole cell lysate, suggesting robust effector‐level response 
against those targets. While these studies were generally limited to probing for 
immunity against well characterized epitopes, it could be reasonably inferred that 
the CpG‐CCNP formulation was concurrently generating additional responses 
against other tumor‐relevant antigens. 
Figure 2.5: Characterization of in vivo T cell responses. a) Proliferation index of 
adoptively transferred pmel‐1 CD8+ T cells after in vivo stimulation by CpG‐CCNPs 
or various control formulations, including whole cell lysate with free CpG (WC + 
fCpG), CCNPs with free CpG (CCNP + fCpG), CCNPs, CpG‐NPs, and blank solution 
(n = 3; mean ± SD). b,c) Tetramer staining analysis of T cells specific for gp100 (b) and 
TRP2 (c) after ex vivo restimulation of splenocytes from mice vaccinated with CpG‐
CCNPs or various control formulations (n = 3; mean ± SD). *p < 0.05, **p < 0.01, 
****p < 0.0001 (compared to CpG‐CCNP); one‐way ANOVA. 
 
 
 
 87 
To assess if the enhanced cellular immunity afforded by the CpG‐CCNP 
formulation could translate into functional rejection of tumor cells, a prophylactic 
study using the wild‐type B16‐F10 model, which is poorly immunogenic [21, 36, 
37], was carried out (Figure 2.6a–c). In mice vaccinated with CpG‐CCNPs, there 
was significant activity, and tumor occurrence was prevented in 86% of mice 150 
d after challenge with the tumor cells. Formulations consisting of either whole cell 
lysate with free CpG or CCNPs with free CpG both showed modest control of 
tumor growth, extending median survival from 20 d for the untreated group to 34 
and 40 d, respectively. All but one of the mice in these groups reached the 
experimental endpoint by day 48 after challenge. CCNPs without adjuvant had 
minimal protective benefit, with the mice in these groups achieving a median 
survival of 28 days. Finally, mice vaccinated with CpG‐NPs that had no antigenic 
material exhibited tumor growth kinetics identical to the blank control and 
displayed a median survival of 22 d. The results suggest that codelivery of both 
tumor antigen material and the CpG adjuvant together in the same vehicle is 
necessary for eliciting maximal antitumor immunity. The fact that CpG‐NPs alone 
had no effect is encouraging and demonstrates that the inclusion of cancer 
membrane material helped to provide appropriate cues for the specific detection 
and elimination of malignant cells by the immune system. 
The utility of the nanoparticulate vaccine formulation was further tested in 
a more clinically relevant therapeutic setting (Figure 2.7a–c). In this study, mice 
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were challenged with B16‐F10 cells and subsequently treated with the 
nanoformulation. Using this design, CpG‐CCNPs alone displayed a modest ability 
to control tumor growth and extend survival. Given the aggressive nature of the 
B16‐F10 tumor model, the results were not unexpected, especially given that 
vaccination largely focuses on the training phase of adaptive immunity. Despite 
Figure 2.6: Prophylactic efficacy. a–c) Mice immunized with CpG‐CCNPs and various 
control formulations, including whole cell lysate with free CpG (WC + fCpG), CCNPs 
with free CpG (CCNP + fCpG), CCNPs, CpG‐NPs, and blank solution, on days 0, 7, 
and 14 were challenged with B16‐F10 cells on day 21. Average tumor sizes (a), survival 
(b), and individual tumor growth kinetics (c) were plotted over time (n = 7; mean ± 
SEM). Reporting of average tumor sizes was halted after the first mouse died in each 
respective group. *p < 0.05, ***p < 0.001 (compared to CpG‐CCNP in survival plot); 
log‐rank test. 
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adequately enabling the immune system to recognize the appropriate targets, 
vaccine formulations for boosting cellular immunity may not be particularly well‐
suited for potentiating effector functionality in the presence of strong 
immunosuppression [38].  As such, the CpG‐CCNPs were combined with a 
checkpoint blockade cocktail consisting of anti‐CTLA4 and anti‐PD1, and 
treatment with the combination enabled significantly enhanced control of tumor 
growth. Median survival was extended from 18 d for the blank control to 32 d for 
the treated group, and 50% of tumors were still below the experimental endpoint  
Figure 2.7: Therapeutic efficacy. a–c) After challenge with B16‐F10 cells on day 0, 
mice were treated using CpG‐CCNPs combined with a checkpoint blockade cocktail of 
anti‐CTLA4 plus anti‐PD1 (αCTLA4/αPD1), CpG‐CCNPs alone, or the checkpoint 
blockade cocktail alone on days 1, 2, 4, and 7. Average tumor sizes (a), survival (b), 
and individual tumor growth kinetics (c) were plotted over time (n = 6; mean ± SEM). 
Reporting of average tumor sizes was halted after the first mouse died in each respective 
group. *p < 0.05, ***p < 0.001 (compared to CpG‐CCNP + αCTLA4/αPD1 in survival 
plot); log‐rank test. 
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threshold on day 48 postchallenge. In contrast, the checkpoint blockades, which  
have not shown significant efficacy in a related B16 model [39], was about as 
effective as CpG‐CCNPs. The results confirm that the nanoparticulate vaccine 
formulation can act synergistically with other immunotherapies, modulating 
different aspects of immunity to promote the strongest antitumor responses. 
 
2.4 Conclusion 
 
In conclusion, we have reported on a biomimetic nanoparticulate anticancer 
vaccine formulation capable of activating multiantigenic immunity. The design 
leverages the unique advantages of recent nanoparticle technology, delivering both 
syngeneic cancer material along with a potent immunological adjuvant in a format 
that promotes effective antigen presentation. The final formulation is capable of 
generating strong antitumor responses in vivo and can work together with other 
immunotherapies such as checkpoint blockades to help control tumor growth. It is 
increasingly understood that presentation of tumor antigens alone, even in highly 
immunogenic contexts, may not be able to overcome the immunosuppressive tumor 
microenvironment [38, 40].  As such, efforts have shifted toward the rational design 
of combinatorial approaches that leverage multiple modes of action [41-
43],  including employing such strategies as adjuvant therapies to surgical resection 
[44].  In doing such, the potential adverse effects of immunomodulatory cocktails 
will also need to be considered [45].  The present nanoparticle‐based cancer cell 
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membrane coating strategy represents a generalizable and effective means of 
boosting endogenous immunity against autologous material, which may, in the 
future, be derived from a patient's own resected primary tumor as a means to 
prevent relapse. All of this is accomplished in a manner that is unique when 
compared to current strategies and can possibly pave the way for enhanced 
personalized anticancer vaccines. 
Chapter 2, in full, is a reprint of the material as it appears in Advanced 
Materials, 2017, Ashley Kroll, Ronnie Fang, Yao Jiang, Jiarong Zhou, Xiaoli Wei, 
Chun Lai Yu, Jie Gao, Brian Luk, Diana Dehaini, Weiwei Gao and Liangfang 
Zhang. The dissertation author was a primary investigator and author of this 
material. 
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3.1 Nanotoxoid for Antivirulence Vaccination 
 
3.1.1 Introduction 
 
 The continued rise of antibiotic‐resistant bacteria has become a significant 
burden on global health and is responsible for an increased rate of life‐threatening 
infections observed in the clinic [1].  The issue continues to rise to the forefront as 
the development of new antibiotics has slowed to a near halt [2],  prompting 
physicians and scientists to explore alternative strategies to control bacterial 
infections [3].  Among the different approaches, antivirulence vaccination is a 
compelling strategy as it promotes host immunity by training the body to detect and 
disarm specific mechanisms employed by pathogens during host invasion [4]. This 
approach has been shown to inhibit the ability of pathogens to colonize within a 
host and is less susceptible to the development of resistance as it does not exert 
direct selective pressure on individual bacterium [5].  Antivirulence vaccination is 
most commonly accomplished through the use of toxoids, or inactivated forms of 
live bacterial toxins, which include the commonly used tetanus toxoid [6]  and 
diphtheria toxoid [7].  Conventionally, these toxoids are prepared by denaturation 
via either chemical or heat treatment in order to eliminate the dangerous effects of 
the original toxin [8].  However, such inactivation methods are often disruptive and 
can lead to altered antigen presentation as well as compromised immunogenicity 
[9].  To overcome the tradeoff between safety and efficacy, emerging techniques 
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are being developed to produce vaccine candidates that faithfully present antigenic 
epitopes for immune processing [10].  
Methicillin‐resistant Staphylococcus aureus (MRSA) is an antibiotic‐
resistant pathogen that represents a significant threat to public health, especially in 
hospital environments where many patients have weakened immune systems that 
are incapable of naturally fending off infection [11].  It can cause severe skin 
lesions and can ultimately be life‐threatening upon systemic invasion [12].  The 
pace of resistance exhibited by MRSA has severely limited treatment options, with 
many strains of the bacteria being unresponsive to all of the most commonly used 
antibiotics [13, 14].  This has led researchers to explore other forms of treatment, 
including the aforementioned antivirulence therapy. Known to secrete many 
different types of exotoxins, MRSA represents a good target for such therapies. One 
of its major virulence factors is α‐hemolysin (Hla) [15],  a toxin that forms 
heptameric pores on cell surfaces, which contributes greatly to the pathogenesis of 
MRSA during the process of infection [16].  In fact, it has been shown that the 
virulence of the pathogen correlates strongly with the level of Hla production [17, 
18].  Further, immunization with a mutant form of Hla has been shown to confer 
protection against Staphylococcus aureus (S. aureus) pneumonia in mice 
[19].  Passive immunization with anti‐Hla antibodies also protected against skin 
lesions caused by subsequent S. aureus infection, further attesting to the utility of 
such a strategy for combating the pathogen. 
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The application of novel nanomaterials toward vaccine design has the 
potential to bring about significant improvements via efficient and finely controlled 
immune manipulation [20-25].  We have previously demonstrated a nanoparticle‐
mediated toxin detainment strategy for the preparation of a safe and potent toxoid 
formulation. Biomimetic nanoparticles are fabricated with a cell membrane‐derived 
coating that presents a natural substrate for pore‐forming toxins [26, 27],  leading 
to their stable entrapment onto the nanoparticles and enabling safe delivery in vivo 
for immune processing [28].  Owing to the nondisruptive approach of this 
detainment strategy, the platform was demonstrated to be superior to a traditionally 
formed toxoid by generating higher anti‐Hla titers with increased avidity. Further, 
vaccination with the detained toxin conferred a significant survival benefit in a 
murine model of lethal toxin challenge. In the present work, we investigated the 
protective capabilities of nanoparticle‐detained staphylococcal Hla, denoted 
nanotoxoid(Hla), against live bacterial challenge using a mouse model of MRSA 
skin infection (Figure 3.1.1). The immune potentiating effect of the nanoparticle 
formulation was studied more in‐depth by looking at the formation of germinal 
centers in the draining lymph nodes (dLNs) of vaccinated mice, which was then 
correlated to anti‐Hla titer production. The ability of the nanotoxoid(Hla) vaccine 
to protect against MRSA infection and lessen bacterial colonization was evaluated 
in a mouse model of skin lesion formation. Beyond local infection, the effect of the 
nanoparticle vaccination on bacterial invasiveness was further studied by 
enumerating the bacterial load in major organs. 
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3.1.2 Experimental Methods 
 
3.1.2.1 Preparation and Characterization of Nanotoxoid(Hla) 
RBC membrane‐coated nanoparticles were prepared as previously 
described[26]. Polymeric cores were made using 0.67 dL g−1 carboxy‐terminated 
50:50 PLGA (LACTEL Absorbable Polymers) with a modified nanoprecipitation 
method. The polymer was dissolved in acetone at a concentration of 10 mg 
mL−1 and added rapidly to 2 mL of deionized water. The mixture was placed under 
vacuum for 3 h to evaporate the organic solvent. To obtain the membrane material, 
Figure 3.1.1: Schematic of nanotoxoid(Hla) protection against MRSA infection. a) 
Under normal conditions, MRSA bacteria employ Hla to help them colonize the site of 
challenge, resulting in significant skin lesion formation and systemic invasiveness. b) 
After vaccination with the nanotoxoid(Hla) formulation, anti‐Hla titers are induced. 
These antibodies neutralize the toxin produced by the MRSA bacteria at the site of 
challenge, reducing the ability of the pathogen to colonize and enter into systemic 
circulation. 
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RBCs collected from 6 week old male CD‐1 mice (Harlan Laboratories) were 
treated with hypotonic medium and washed multiple times by centrifugation. The 
final RBC membrane‐coated nanoparticles, denoted nanotoxoid(‐), were 
synthesized by sonicating a mixture of the PLGA cores and RBC membrane using 
a Fisher Scientific FS30D bath sonicator at a frequency of 42 kHz and a power of 
100 W for 2 min. The membrane material from 1 mL of mouse blood was used to 
coat 5 mg of 100 nm PLGA cores. The nanotoxoid(Hla) was generated by 
incubating 0.2 mg of nanotoxoid(‐) with 3 μg of Hla at 37 °C for 15 min. 
Nanoparticle concentrations for both the nanotoxoid(Hla) and nanotoxoid(‐) 
formulations were expressed as milligrams of PLGA per 1 mL of solution (mg 
mL−1). The mixture was then filtered through a Sepharose CL‐4B (Sigma‐Aldrich) 
column to obtain purified nanotoxoid(Hla) free of unbound toxin. The size and the 
zeta potential of the different nanoformulations were measured by dynamic light 
scattering using a Malvern ZEN 3600 Zetasizer. The structure of the 
nanotoxoid(Hla) was examined using a Zeiss Libra 120 PLUS EF‐TEM 
Transmission Electron Microscope. Samples were negatively stained with 0.1 wt% 
uranyl acetate prior to visualization. 
 
3.1.2.2 Nanotoxoid(Hla) Loading Analysis 
 An immunogold staining assay was carried out to confirm insertion of Hla 
onto the RBC membrane‐coated nanoparticles. One drop of nanotoxoid(Hla) or 
nanotoxoid(‐) solution was added onto a glow‐discharged carbon‐coated 400‐mesh 
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copper grid (Electron Microscopy Sciences). The grids were then washed before 
subjecting to blocking with 1 wt% bovine serum albumin (BSA), primary 
immunostaining with polyclonal rabbit anti‐Hla antibody (Sigma‐Aldrich), and 
secondary staining with gold‐labeled anti‐rabbit IgG antibody (Sigma‐Aldrich). 
Images were obtained using a Zeiss Libra 120 PLUS EF‐TEM Transmission 
Electron Microscope without negative staining. To analyze Hla retention by dot 
blot analysis, 1 μL of nanotoxoid(Hla) solution at 2 mg mL−1 was dropped onto a 
nitrocellulose membrane and allowed to fully dry under vacuum. Afterward, the 
membrane was blocked with 1 wt% BSA solution and then probed with a 
polyclonal rabbit anti‐Hla primary antibody (Sigma‐Aldrich) followed by a donkey 
antirabbit IgG‐horseradish peroxidase (HRP) conjugate secondary antibody 
(Biolegend). The blot was developed with ECL western blotting substrate (Pierce) 
using a Mini‐Medical/90 Developer (ImageWorks). Nanotoxoid(‐) solution at 2 mg 
mL−1 was used as negative control and Hla solution corresponding to 100% loading 
(30 μg mL−1) was used as positive control. Blot intensity was measured by 
analyzing the mean gray values of dots via Image J software. 
 
3.1.2.3 Germinal Center Analysis 
All animal experiments followed protocols that were reviewed, approved, 
and performed under the regulatory supervision of the University of California, San 
Diego's institutional biosafety program and the Institutional Animal Care and Use 
Committee. Six‐week old male CD‐1 mice (Harlan Laboratories) were immunized 
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subcutaneously in the lateral tarsal region just above the ankle with 0.1 mg of 
nanotoxoid(Hla). Nanotoxoid(‐) and PBS were used as negative controls. On day 
21 postimmunization, the mice were euthanized and the draining popliteal lymph 
nodes were collected for analysis. For immunohistochemical analysis, the lymph 
nodes were cryosectioned and stained with antimouse/antihuman B220‐Pacific 
Blue, antimouse IgD‐Alexa Fluor 488, and antimouse/antihuman GL‐7‐Alexa 
Fluor 647 antibodies (Biolegend). For flow cytometry analysis, Lymph nodes were 
digested in 1 mg mL−1collagenase D (Roche) solution and stained with the above 
antibodies. Data were collected using a BD FACSCanto‐II flow cytometer and 
analyzed using FlowJo software. 
 
3.1.2.4 Anti-Hla Titer Analysis 
Mice were subcutaneously administered with 0.1 mg of nanotoxoid(Hla), 
0.1 mg of nanotoxoid(‐) or PBS, followed by a boost 14 days later (n = 6). On days 
0, 14, and 35, the serum of each mouse was collected to assay for Hla‐specific 
antibody titers by an enzyme‐linked immunosorbent assay (ELISA). A 96‐well 
plate was coated overnight with 2 μg ml−1 Hla using commercial coating buffer 
(Biolegend). The wells were then blocked with 5 wt% milk before adding serially 
diluted serum samples as the primary antibody. Goat antimouse IgG‐HRP 
(Biolegend) was then employed as the secondary antibody. The plate was 
developed with 1‐Step Slow TMB‐ELISA substrate (Pierce) and measured at 450 
nm with a Tecan Infinite M200 Multiplate Reader. 
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3.1.2.5 MRSA Infection and Vaccine Efficacy 
The MRSA strain USA300 TCH1516 (American Type Culture Collection) 
was used in this study. The bacteria were cultured at 37 °C in tryptic soy broth, 
harvested by centrifugation, washed, suspended with PBS, and adjusted to the 
appropriate concentration by optical density measurements before use. Mice 
immunized with 0.1 mg of nanotoxoid(Hla), 0.1 mg of nanotoxoid(‐), or PBS on 
days 0 and 14 were challenged with 1 × 109 CFU of the bacteria on day 35. The 
bacteria were inoculated subcutaneously in the back region in an area that was 
carefully shaved using hair clippers before the challenge. The dermonecrotic area 
was monitored daily and reported as the width multiplied by the length of the visible 
lesion. On day 6 postchallenge the mice were euthanized; perfused with PBS via 
the heart; and the skin, heart, liver, spleen, lung, and kidney of each mouse were 
excised and processed for enumeration. Briefly, organs were homogenized in sterile 
PBS using a Biospec Mini BeadBeater, diluted tenfold serially with PBS, plated 
onto tryptic soy agar, and finally the colonies were counted after 24 h of incubation 
at 37 °C. 
 
3.1.3 Results and Discussion 
 
Nanoparticles coated with red blood cell (RBC) membrane were prepared 
using a previously described protocol [29]. Briefly, mouse RBCs were subjected to 
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hypotonic treatment to obtain purified RBC membrane ghosts, which were then 
fused onto the surface of preformed nanoparticle cores made using poly(lactic‐co‐
glycolic acid) (PLGA) through a sonication method. As the RBC membrane coating 
serves as a natural substrate for the pore‐forming Hla, nanotoxoid(Hla) complexes 
were formed by incubating free Hla with unloaded nanoparticles, herein denoted 
nanotoxoid(‐). Free Hla was subsequently removed from the nanotoxoid(Hla) 
complexes by size exclusion chromatography to obtain a purified formulation. 
Physicochemical characterization showed that the resulting nanotoxoid(Hla) was 
about 115 nm in diameter and had a surface zeta potential of −32 mV (Figure 
3.1.2a,b), both of which were similar to those of the unloaded nanotoxoid(‐), 
suggesting that toxin insertion did not have a major impact on overall nanoparticle 
properties. This was further confirmed via transmission electron microscopy 
(TEM) of negatively stained nanotoxoid(Hla), which revealed that the 
characteristic core–shell structure of the RBC membrane‐coated nanoparticle was 
preserved even after toxin loading, consistent with what has been previously 
observed [26, 28] (Figure 3.1.2c). 
To confirm successful detainment of Hla by the RBC membrane‐coated 
nanoparticles, different immunoassays were performed. On the TEM image, Hla‐
specific antibody labeling of nanotoxoid(Hla) followed by secondary labeling using 
an immunogold conjugate showed significant colocalization of the electron‐dense 
gold signal with regions of intermediate density occupied by the nanoparticles, 
indicating a significant presence of Hla‐specific epitopes on the nanotoxoid(Hla) 
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(Figure 3.1.2d). Conversely, no gold signal could be detected in the nanotoxoid(‐) 
sample subjected to the exact same staining procedure, confirming that the positive 
signal seen in the nanotoxoid(Hla) was not due to nonspecific antibody staining. 
Note that in the absence of negative staining, the morphological appearance of the 
nanotoxoid differs from what is observed in Figure 3.1.3c. The uranyl acetate stain 
can act as a fixative, serving to stabilize the nanoparticles and to enhance the core–
shell structure of the nanoparticles. Dot blot analysis was used to further confirm 
the presence of Hla on nanotoxoid(Hla) samples (Figure 3.1.2e). Using anti‐Hla as 
the primary immunostain, nanotoxoid(Hla) gave a positive signal whereas 
nanotoxoid(‐) did not give any discernable signal. As a positive control, free Hla at 
the initial input concentration used to prepare nanotoxoid(Hla) was tested in 
parallel, and image analysis of the blot intensities revealed that ≈95% of the Hla 
was retained on the nanoparticles after purification, suggesting high affinity of the 
toxin for the membrane‐coated nanoparticles. It has been shown previously that the 
strong sequestration of toxin by the nanoparticle detainment strategy resulted in 
little release over time, which effectively neutralized the activity of the toxin and 
enables safe delivery both in vitro and in vivo [28]. 
Next, the ability of the nanotoxoid(Hla) formulation to promote anti‐Hla 
immune responses was studied. Of particular interest was the formation of germinal 
centers (GCs), which is a critical step in the potentiation of the humoral immune 
response against foreign antigens [30, 31].  It is in these regions that B cells mature, 
and it has been shown that improved retention of antigens via nanoparticle‐ 
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mediated delivery can better facilitate GC formation [32].  We therefore sought to  
evaluate lymphatic B cell activation in mice immunized with the nanotoxoid(Hla) 
formulation. Immunostaining was employed to detect the presence of GCs in the 
dLNs of mice immunized subcutaneously with the nanoformulation. PBS and 
unloaded nanotoxoid(‐) were administered as controls. Histological analysis of the 
dLNs from mice immunized with nanotoxoid(Hla) revealed GL‐7+ regions 
Figure 3.1.2: Nanotoxoid(Hla) characterization. a) Size and b) zeta potential of 
nanotoxoid(‐) [denoted “NT(‐)”] and nanotoxoid(Hla) [denoted “NT(Hla)”] (n = 3). 
Error bars represent standard deviation. c) TEM image of nanotoxoid(Hla) after 
negative staining with uranyl acetate. Scale bar = 100 nm. d) TEM images of 
immunogold‐stained NT(‐) (left) and NT(Hla) (right) with anti‐Hla as the primary 
immunostain and gold‐labeled anti‐IgG as the secondary stain. The gold (≈10 nm) 
appears as dark punctates on the images. Scale bar = 100 nm. e) Dot blotting results 
using anti‐Hla as the primary immunostain. Quantification by image analysis revealed 
that 95.2% of the Hla input was retained on the final NT(Hla) formulation. 
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characteristic of GC nucleation (Figure 3.1.3a). In contrast, there was no visual 
evidence of GC formation in the PBS or nanotoxoid(‐) immunization groups, 
confirming the nonimmunogenicity of the naturally derived nanoparticle vector 
itself [33].  Flow cytometry results (Figure 3.1.3b) showed that 45.6% of 
B220+IgDlow B cells in the dLNs of the nanotoxoid(Hla) group exhibited a GL‐
7+ germinal center phenotype. In contrast, only 15.7% and 13.6% of cells in mice 
administered with PBS and nanotoxoid(‐), respectively, exhibited the same 
phenotype. 
The ability of nanotoxoid(Hla) to elicit a humoral immune response against 
Hla was further investigated. Mice were subcutaneously injected with 
nanotoxoid(Hla), nanotoxoid(‐), or PBS on day 0 and were subsequently 
administered a booster on day 14. The serum of the mice in each group was sampled 
on days 0, 14, and 35 to assess Hla‐specific IgG titers (Figure 3.1.3c–e). 
Nanotoxoid(Hla) vaccination elicited significant anti‐Hla titers on day 14, and there 
was a further increase when assayed on day 35. In contrast, the nanotoxoid(‐) and 
PBS vaccinations resulted in no detectable anti‐Hla titers over the course of the 
study. The nanotoxoid(Hla)‐induced antibody responses have previously been 
shown to be durable, with little to no drop in titers over the course of a five‐month 
period [28].  Taken together, the data demonstrates that the nanotoxoid(Hla) 
formulation can effectively elicit potent anti‐Hla immune responses, despite 
complete deactivation of the toxin [26].  This is notable finding given that the 
formulation is absent of immunological adjuvants, which are commonly required 
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for conventional toxoid formulations and help to boost germinal center antibody 
activity [34].  
To evaluate the protective capability of the nanotoxoid(Hla) vaccine  
against MRSA infection, we employed a mouse skin infection model. MRSA 
represents one of the most common causes of skin infections, both in the 
community and in hospitals [12].  Because the pathogen is hard to treat with 
Figure 3.1.3: Germinal center formation and antibody production induced by 
nanotoxoid(Hla) vaccination. a,b) Mice were vaccinated with PBS, nanotoxoid(‐) [NT(‐
)], or nanotoxoid(Hla) [NT(Hla)] (n = 3). The draining lymph nodes were collected 21 
d later for the analysis of B220 (blue), IgD (green), and GL‐7 (red) expression by either 
immunohistochemistry (a) or flow cytometry (b). Scale bars = 250 μm. For flow 
cytometric analysis, cells were first gated on B220+IgDlow and the numbers reported are 
the percentage GL‐7+ cells within that population. Error bars represent the standard 
error. Statistical significance was determined by one‐way ANOVA (**P < 0.01). c–e) 
Mice were vaccinated with PBS, NT(‐), or NT(Hla) on day 0 with a boost on day 14 
(n = 6). On days 0 (c), 14 (d), and 35 (e), serum was collected and the anti‐Hla IgG 
titers were quantified by ELISA. Lines represent geometric means. 
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common antibiotics, the infection can quickly progress and lead to serious 
complications, from physical disfigurement to permanent organ damage, and in 
many cases even death. For this experiment, mice were immunized with 
nanotoxoid(Hla) on day 0 and given a booster dose on day 14. Mice injected with 
nanotoxoid(‐) or PBS were used as control groups. On day 35, the mice were 
subcutaneously challenged with live MRSA bacteria, and the efficacy in the 
different experimental groups was assessed over time by monitoring the 
dermonecrotic area resulting from bacterial burden. The progression of skin lesion 
development in mice immunized with nanotoxoid(Hla) was significantly attenuated 
compared with mice in the nanotoxoid(‐) and PBS groups, which both experienced 
rapid lesion formation (Figure 3.1.4a,b). On day 6 postinfection, there was an 
approximately fivefold reduction in dermonecrotic area on mice treated with the 
nanotoxoid(Hla) formulation compared to the control groups. 
At the conclusion of the observation period, the bacterial burden was 
quantified in the infected skin region of each mouse (Figure 3.1.4c). For the 
nanotoxoid(‐) and PBS groups, the bacterial burdens of the infected skin tissue were 
1.7 × 107 and 2.2 × 107 CFU, respectively. Mice immunized with nanotoxoid(Hla) 
showed an average burden of 1.5 × 106 CFU, representing 11.3‐ and 14.7‐fold 
reductions compared with the nanotoxoid(‐) and PBS groups, respectively. It has 
previously been shown that nanotoxoid(Hla) is capable of significantly inhibiting 
Hla‐mediated skin damage in the subcutaneous space, suggesting that the titers 
generated by the formulation are sufficiently high to enable extravascular 
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neutralizing activity [28].  This prevents the necrotic effect of high Hla 
concentrations [35],  thus preserving integrity of the local tissue. In this study, the 
nanoparticle vaccine formulation was likewise able to reduce skin lesion formation, 
demonstrating its ability to facilitate neutralization of Hla produced by the 
bacteria in situ upon subcutaneous challenge. Given the importance of Hla in 
MRSA pathogenesis, neutralization of the toxin also resulted in decreased bacterial 
burden, likely due to increased clearance by immune cells protected from the 
cytotoxic activity of Hla [36].  Despite the significant reduction in both lesion 
formation and bacterial load at the site of infection, the inability of the 
nanotoxoid(Hla) to completely mitigate disease suggests a sizable role played by 
other virulence factors, which can serve as targets for future nanotoxoid vaccine 
formulations. 
MRSA infections can quickly progress and enter systemic circulation, 
leading to a markedly worse prognosis in the clinic [11].  Patients with invasive 
MRSA can precipitously develop life‐threatening infections in different organs 
such as the blood, heart, bone, and kidney. As an MRSA skin infection runs the 
significant risk of further dissemination, the effect of nanotoxoid(Hla) vaccination 
on MRSA invasiveness after subcutaneous challenge was studied. Mice were  
vaccinated with nanotoxoid(Hla), nanotoxoid(‐), or PBS on day 0 with a booster 
dose on day 14 and subcutaneously inoculated with MRSA on day 35. On day 6 
postinfection, the bacterial counts in the heart, kidney, spleen, lung, and liver were 
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analyzed (Figure 3.1.5). In most of the organs that were analyzed, the 
nanotoxoid(Hla) group showed a significant drop in bacterial burden compared to  
the nanotoxoid(‐) and PBS control groups. Of note, the kidney and spleen, two 
organs that traditionally experience heavy bacterial burden per unit weight [37], 
both had reductions of approximately two orders of magnitude. The sharp decrease 
in organ penetration can likely be attributed primarily to better immune 
management at the site of infection, which results in improved integrity of the skin 
Figure 3.1.4: Effect of nanotoxoid(Hla) vaccination on MRSA skin colonization. Mice 
vaccinated with PBS, nanotoxoid(‐) [NT(‐)], or nanotoxoid(Hla) [NT(Hla)] on days 0 
and 14 were challenged subcutaneously with 1 × 109 CFU of MRSA bacteria on day 
35. a) The skin lesions were monitored over the course of 6 d (n = 6). Error bars 
represent the standard error. b) Images of skin lesions on day 6 postinfection. Scale bar 
= 1 cm. c) On day 6 postinfection, the affected skin and underlying tissue were collected 
and the bacterial burden enumerated (n = 6). Lines represent the geometric mean. 
Statistical significance determined by one‐way ANOVA (**P < 0.01). 
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protective barrier and fewer bacteria entering the circulation system. Additionally, 
the presence of high amounts of neutralizing titers within the body can further 
hamper the capacity of invading MRSA bacteria to colonize individual organs, as 
shown by previous studies on the effect of anti‐Hla vaccination in animal models 
of sepsis [38].  Overall, the results demonstrate that nanotoxoid(Hla) not only 
prevents superficial damage, but also decreases MRSA invasiveness, which can 
ultimately help to prevent many of the harsh complications associated with MRSA 
infections.  
Figure 3.1.5: Effect of nanotoxoid(Hla) vaccination on MRSA invasiveness. Mice 
vaccinated with PBS, nanotoxoid(‐) [NT(‐)], or nanotoxoid(Hla) [NT(Hla)] on days 0 
and 14 were challenged subcutaneously with 1 × 109 CFU of MRSA bacteria on day 35. 
On day 6 postinfection, the major organs, including the a) heart, b) kidney, c) spleen, d) 
lung, and e) liver were collected and the bacterial burden of each was enumerated (n = 
6). Lines represent geometric means. Statistical significance was determined by one‐
way ANOVA (**P < 0.01, ***P < 0.001, and ****P < 0.0001). 
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3.1.4 Conclusion 
 
This study investigated the use of nanoparticle‐detained toxins for 
antivirulence vaccination as a prophylactic strategy against live MRSA skin 
infection. Such strategies address an important need in the clinical management of 
bacterial infections as the rise of antibiotic resistance has been difficult to overcome. 
An increasing emphasis has been placed on novel strategies that transcend 
traditional treatment paradigms. The nanotoxoid(Hla) has been shown capable of 
safely delivering the Hla toxin in its native form without the need for subunit 
engineering or denaturation. Additionally, the anti‐Hla titers elicited by the 
nanoformulation are of high avidity and long‐lived. In this study, we demonstrated 
that nanotoxoid(Hla) was capable of promoting strong humoral immunity in an 
adjuvant‐free setting via efficient germinal center formation. Using a mouse skin 
infection model, it was demonstrated that immunity could substantially attenuate 
the ability of live bacteria to colonize and systemically invade their hosts, which 
could ultimately abrogate the negative consequences of severe MRSA infections. 
Successful validation of nanotoxoid(Hla) vaccination for protection against 
live MRSA challenge opens the door for further development of similar platforms 
against many other common yet deadly bacterial pathogens. Pore‐forming toxins 
are one of the most common protein toxins found in nature and represent a large 
class of virulence factors that have natural affinity for cell membrane substrates 
[39],  and the reported detainment strategy has been shown effective in neutralizing 
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such toxins secreted by several different organisms, including S. aureus, 
Escherichia coli, and Helicobacter pylori [26].  By targeting the common 
mechanism by which many virulence factors function, the nanotoxoid formulation 
can be applied to an entire class of toxins without specific knowledge of each toxin's 
precise molecular structure. This strategy opens the door for the nanotoxoid to be 
used as a diverse vaccine carrier for multitoxin vaccination, as many pathogens 
secrete multiple membrane‐attacking virulence factors [40].  By presenting 
multiple virulent antigens, nanotoxoid can further increase vaccine efficacy and 
limit bacterial colonization. In addition, changing the membrane coating material 
[41-43]  could further broaden applicability to toxins that do not specifically target 
RBCs. Overall, the nanoparticle‐based antivirulence vaccine platform is primed to 
help usher in a new generation of treatments that can address some of the most 
critical needs in the current management of bacterial infections. 
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3.2 In Situ Multiantigenic Nanotoxoid for Antivirulence 
Vaccination 
 
3.2.1 Introduction 
 
The continued rise of antibiotic‐resistant bacteria poses a significant threat to 
public health, yet the development of new small‐molecule antibiotics remains slow 
[1].  An increasing number of lives will be at risk as time progresses, and thus 
finding new and innovative ways to combat these potentially lethal pathogens is of 
extremely high importance [2-6].  Along these lines, antivirulence therapy is a 
promising strategy for addressing bacterial infection that focuses on removing the 
offensive weapons used by bacteria to successfully colonize a host [7-9].  Examples 
of such factors include protein‐based toxins, which can be used to attack host cells 
via physical disruption, biochemical degradation, or signaling interruption, thereby 
preventing immune clearance and providing the nutrients necessary for 
proliferation [10, 11].  Neutralization of these bacterial virulence factors can have 
a marked impact on bacteria survivability [12].  One major advantage of employing 
antivirulence therapy is that, unlike with antibiotics, the treatment itself does not 
exert direct selective pressure on individual bacterium; by focusing instead on 
blocking pathogen‐to‐host interactions, this strategy can ultimately translate into a 
reduced likelihood of developing resistance [13].  Implementation of this strategy 
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has varied, ranging from traditional antibody neutralization [14, 15],  to novel 
nanotechnology‐based complexation [16-19].  While antivirulence can be effective 
in therapeutic settings, arguably the most impactful applications center around 
prophylactic vaccination. In fact, commonly used vaccines in the clinic against 
diphtheria and tetanus are targeted against their respective virulence factors [20], 
underscoring the usefulness of this strategy. 
While the immunity generated through antivirulence vaccination can be used 
to effectively prevent some bacterial infections, others have proven much more 
difficult to address [21].  A major challenge for creating vaccines against biological 
toxins is the balance that must be struck between safety and immunogenicity, which 
often exhibit an inverse relationship [22]. Toxicity can be attenuated via several 
different approaches, including heat treatment and chemical modification [23]; 
however, not all toxins are heat‐labile, and denaturation has the potential to 
compromise vaccine efficacy due to the modified presentation of epitopic target 
s[24]. Subunit engineering can eliminate virulence, but requires significant upfront 
investment of resources and is only applicable towards well‐characterized targets 
[25].  Vaccine potency is further challenged by the varying secretion profiles of 
different bacterial species and strains. As many bacteria produce a wide variety of 
toxins and other factors [26, 27],  it can be difficult to pinpoint which of these are 
major contributors to pathogenesis. In some cases, vaccination approaches based 
on multiple known toxins have been shown to carry great utility [28],  but these are 
hard to pursue given the significant time required for identification and 
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confirmation of new virulence factors. While such approaches will undoubtedly be 
aided by advances in genomic and proteomic technologies, the history of some 
well‐known toxins, such as streptolysin S secreted by group A streptococcus, 
underscores the gap that often exists between knowledge and application [29].  
To circumvent the need for identification of individual virulence factors, 
direct derivation from bacterial protein secretions should represent an attractive 
method to obtain the material needed for generating antivirulence vaccines. 
However, this strategy has seldom been studied [30, 31], likely also due to issues 
in balancing safety and immunogenicity, with the added challenge of having to 
manage the presence of irrelevant proteins that dilute immune focus. In this work, 
we report on a facile approach for generating on‐demand nanotoxoids from 
naturally derived bacterial protein preparations by leveraging the near universal 
natural affinity of virulence factors for cellular membranes [16, 32] (Figure  3.2.1). 
Virulent proteins are biomimetically entrapped using a membrane‐coated 
nanosponge construct [17],  effectively modulating the surface material 
composition for custom vaccine applications. Following a generalizable workflow 
that does not require prior knowledge of secreted constituents, pathogen‐specific 
formulations that are safe, potentially multiantigenic, and epitopically faithful can 
be fabricated. The feasibility of this approach is demonstrated using methicillin‐
resistant Staphylococcus aureus (MRSA), which employs multiple well‐
characterized toxins [26, 33],  as the model pathogen, along with red blood cell 
(RBC) membrane‐coated nanosponges as the model vector. 
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3.2.2 Experimental Methods 
 
3.2.2.1 Preparation of Hemolytic Secreted Protein Fraction 
The MRSA strain USA300 (BAA‐1717; American Type Culture 
Collection) was first plated onto a tryptic soy agar (Sigma Aldrich) plate overnight 
at 37 °C. A single colony was cultured in 5 mL of tryptic soy broth (TSB; Sigma 
Aldrich) for 24 h at 37 °C, and 1 mL was then transferred to another 100 mL of 
TSB and cultured for 24 h. The media were collected after spinning down the 
bacteria at 3 000 × g for 20 min. Saturated ammonium sulfate (Sigma Aldrich) 
Figure 3.2.1: Schematic depicting on‐demand fabrication of a pathogen‐specific 
nanotoxoid and its vaccination benefits. A) Pathogens secrete virulence factors, 
which are capable of inserting into target cells and causing their destruction. B) Using 
nanosponges prepared with the membrane of target cells and incubating the particles 
with a bacterial supernatant‐derived protein fraction, it is possible to generate a 
nanotoxoid carrying pathogen‐specific virulence factors. C) After vaccination using 
the nanotoxoid, antibodies against the incorporated virulence factors are elicited and 
can prevent their toxic effects, leaving the intended targets unharmed. 
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solution was added slowly to the media in a glass beaker while stirring at 4 °C up 
to a 25% volume ratio. After stirring for 1 h, the solution was centrifuged at 3 000 
× g for 20 min to pellet the first fraction. Fractions at 50% and 75% volume ratios 
were collected in the same manner. Finally, solid ammonium sulfate was added to 
obtain the equivalent of a 95% saturated solution volume ratio and stirred overnight 
before collection of the last fraction. All precipitated protein pellets were dissolved 
in water and desalted using columns packed with fine G‐25 Sephadex (GE 
Healthcare). Only the first protein fraction to pass through each column was 
collected, ultimately yielding concentrated samples free from most other 
nonprotein contaminants. Hemolytic activity was assessed by adjusting protein 
solutions to 1× phosphate buffered saline (PBS) and incubating at 1 mg mL−1with 
an equal volume of 2.5% purified RBCs collected from male ICR mice (Envigo). 
All animal experiments were performed in accordance with NIH guidelines and 
approved by the Institutional Animal Care and Use Committee (IACUC) of the 
University of California, San Diego. After 30 min of incubation, the samples were 
spun down at 2 000 × g for 5 min. Hemolysis was determined by measuring the 
absorbance of the supernatant at 540 nm using a Tecan Infinite M200 plate reader. 
Fractions demonstrating considerable signal were combined together for further use 
as the hSP fraction. 
 
3.2.2.2 Preparation and Physicochemical Characterization of Nanosponges 
and Nanotoxoid(hSP) 
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RBC‐membrane‐coated nanosponges were prepared by a previously 
reported method[34]. Membrane vesicles collected from male ICR mice were 
coated by a sonication process onto preformed polymeric cores prepared with 
carboxyl‐terminated poly(lactic‐co‐glycolic acid) (0.67 dL g−1, 50:50 monomer 
ratio; LACTEL Absorbable Polymers). To assess the ability of nanosponge 
preincubation to prevent hemolysis by the hSP fraction, 400 µg of the nanosponges 
was incubated with varying amounts of protein ranging from 1 to 50 µg in 10 wt% 
sucrose at 37 °C for 30 min. The mixtures in a volume of 100 µL were added to an 
equal volume of 2.5% mouse RBCs in PBS. Equivalent amounts of free hSP in the 
absence of nanosponges were used for comparison. After another 30 min of 
incubation at 37 °C, samples were spun down at 2 000 × g for 5 min. Hemolysis 
was determined by measuring the absorbance of the supernatant at 540 nm using a 
Tecan Infinite M200 plate reader. A 100% lysis control was prepared by treating 
the RBCs with Triton X‐100 (Sigma Aldrich). Subsequent studies were carried out 
using a ratio of 400 µg nanosponges incubated directly with 15 µg of hSP, the 
product of which was referred to as the nanotoxoid(hSP) formulation. The size and 
the surface zeta potential of the nanoformulations were measured by dynamic light 
scattering using a Malvern ZEN 3600 Zetasizer. The structure of the 
nanotoxoid(hSP) was examined after negative staining with 1 wt% uranyl acetate 
(Electron Microscopy Sciences) on a carbon‐coated 400‐mesh copper grid 
(Electron Microscopy Sciences) using a Zeiss Libra 120 PLUS EF‐TEM 
transmission electron microscope. 
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3.2.2.3 Protein Characterization 
To visually confirm the presence of bacterial virulence factors on the 
resulting nanotoxoid(hSP), dot blots were performed to probe for three known 
toxins secreted by MRSA (α‐toxin, PVL, and γ‐toxin). In addition to hSP, 
nanosponge, and nanotoxoid(hSP), a washed nanotoxoid(hSP) sample was 
obtained by centrifugation at 21 100 × g to separate out unbound proteins. 
Nanoparticle samples were run at equivalent nanosponge concentrations, and hSP 
was run at the same concentration as inputted into the nanotoxoid(hSP) formulation. 
The samples were prepared using lithium dodecyl sulfate sample loading buffer 
(Invitrogen), heated at 70 °C for 15 min, and 5 µL of each was dropped onto a 
nitrocellulose membrane (Thermo Scientific) followed by drying under vacuum. 
Membranes were probed using either a polyclonal rabbit anti‐staphylococcal α‐
toxin (Sigma Aldrich), polyclonal rabbit anti‐PVL LukS subunit (IBT Bioservices), 
or polyclonal rabbit anti‐staphylococcal γ‐toxin B (IBT Bioservices) as the primary 
antibody along with an HRP‐conjugated anti‐rabbit IgG (Biolegend) as the 
secondary antibody. Blots were developed with ECL western blotting substrate 
(Pierce) using an ImageWorks Mini‐Medical/90 Developer. 
Western blotting was carried out to quantitatively determine the amount of 
toxins that remained bound to the nanoparticles. Nanotoxoid(hSP) and washed 
nanotoxoid(hSP) were prepared in the same manner as above and run on NuPAGE 
Novex 4%–12% Bis‐Tris minigels (Invitrogen) in MOPS running buffer 
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(Invitrogen). After transferring onto nitrocellulose membranes, the blots were 
probed for α‐toxin, PVL LukS subunit, or γ‐toxin B. Band intensities were 
measured using Adobe Photoshop and normalized to the average values of the no 
wash nanotoxoid(hSP) sample for each toxin. To determine the composition of the 
final hSP preparation, different dilutions of the hSP protein, alongside purified α‐
toxin (Sigma Aldrich), PVL LukS subunit (IBT Bioservices), and γ‐toxin B (IBT 
Bioservices), were subjected to western blot analysis. Linear standard curves were 
generated using the hSP dilutions upon probing for each toxin. Composition 
percentages were determined as the concentration of each purified toxin divided by 
the interpolated hSP concentration based on the band intensities measured for that 
specific toxin (n = 3; mean ± SD). To perform the release study, nanotoxoid(hSP) 
at a concentration of 2 mg mL−1 was placed into a 300 kDa MWCO Float‐A‐Lyzer 
G2 (Spectrum Laboratories) and dialyzed against 2 L of 1× PBS. Samples were 
collected at 0 and 48 h and probed for α‐toxin, PVL LukS subunit, or γ‐toxin B by 
western blotting. Values were normalized to the average band intensities of the 0 h 
samples for each toxin. 
 
3.2.2.4 In Vitro Safety 
 To assess hemolytic activity, hSP (15 µg), heat‐treated hSP (15 µg heated 
for 4 h at 100 °C), nanosponge (400 µg), and nanotoxoid(hSP) (400 µg of 
nanosponge incubated with 15 µg of hSP for 30 min) were added in 150 µL of 
solution to an equal volume of 2.5% mouse RBCs in PBS. Note that the 
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nanoparticle concentration employed was near the maximum feasible value 
allowed by the nanotoxoid fabrication process. After 30 min of incubation at 37 °C, 
each sample was spun down and the absorbance of hemoglobin in the supernatant 
was measured at 540 nm using a Tecan Infinite M200 plate reader. Bone marrow‐
derived dendritic cells were isolated from ICR mice and cultured as reported 
before[35]. To assess cytotoxicity, the cells were plated into 96‐well plates and 
incubated with hSP (7.5 µg), heat‐treated hSP (7.5 µg), nanosponge (200 µg), or 
nanotoxoid(hSP) (200 µg nanosponge with 7.5 µg hSP). After 24 h of incubation 
with the different samples, the cells were cultured for another 48 h in fresh media. 
Cell viability was assayed using an MTT reagent (Invitrogen) following the 
manufacturer's instructions. Untreated cells were used as the 100% viability 
control. 
 
3.2.2.5 In Vivo Safety 
Male ICR mice were first shaved to remove the hair on their back. 
Subsequently, 150 µL of blank solution, hSP (22.5 µg), heat‐treated hSP (22.5 µg), 
nanosponge (600 µg), or nanotoxoid(hSP) (600 µg nanosponge with 22.5 µg hSP) 
was injected subcutaneously. After 48 h, the mice were euthanized, and skin 
samples at the site of injection, where most of the nanoparticles were expected to 
remain, were collected for histological processing. Sections were stained either by 
hematoxylin and eosin (H&E) using SelecTech reagents (Leica Biosystems) or by 
TUNEL using an ApopTag peroxidase in situ apoptosis detection kit (EMD 
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Millipore). Bright‐field images were acquired using a Hamamatsu Nanozoomer 
slide scanning system. 
 
3.2.2.6 Germinal Center Formation 
Six‐week‐old male ICR mice were administered with blank solution, heat‐
treated hSP (7.5 µg), nanosponge (200 µg), or nanotoxoid(hSP) (200 µg 
nanosponge with 7.5 µg hSP) by hock injection. On day 21 after immunization, the 
draining popliteal lymph nodes were collected for analysis. For 
immunohistochemistry, the lymph nodes were cryosectioned and stained with 
Pacific Blue‐labeled anti‐mouse/human B220 (Clone: RA3‐6B2; Biolegend), 
Alexa488‐labeled anti‐mouse IgD (Clone: 11‐26c.2a; Biolegend), and Alexa647‐
labeled anti‐mouse/human GL‐7 (Clone GL7; Biolegend). Fluorescence imaging 
was conducted on a Keyence BZ‐9000 microscope. For flow cytometric analysis, 
the popliteal lymph nodes were dissociated into single cell suspensions using 1 mg 
mL−1 collagenase D (Roche) and 1 mg mL−1 DNAse I (Roche). The cells were then 
stained with the above antibodies followed by data collection on a BD FACSCanto‐
II flow cytometer. Analysis was performed using Flowjo software. 
 
3.2.2.7 Antibody Titer Responses 
Six‐week‐old male ICR mice were vaccinated by subcutaneous injections 
at the neck region with blank solution, heat‐treated hSP (75 µg), or 
nanotoxoid(hSP) (2 mg of nanosponge with 75 µg hSP) on days 0, 7, and 14. On 
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day 21, the blood of each mouse was collected, and the serum was subsequently 
derived by centrifugation at 700 × g. Antibody titers were assessed by an indirect 
ELISA using plates coated with purified α‐toxin, PVL LukS subunit, or γ‐toxin A 
(IBT Bioservices) following a previously reported protocol [12].  
 
3.2.2.8 Protective Efficacy against MRSA Infection 
Six‐week‐old male ICR mice were immunized using the same formulations 
and schedule as above. For the subcutaneous model, 1 × 109 CFU of MRSA 
USA300 was inoculated into the shaved back region away from the site of 
vaccination on day 35. The lesion on the skin of each mouse was monitored daily 
and reported as the width multiplied by the length of the visibly affected area. For 
the systemic model, 2 × 106 CFU of MRSA USA300 was injected via the tail vein. 
On day 3 after challenge, the blood was first collected prior to euthanasia. The mice 
were then perfused with PBS, and the liver, spleen, heart, lungs, and kidneys of 
each mouse were collected and processed for bacterial enumeration following a 
previously published protocol [12]. To obtain the total bacteria count, the values 
from all collected organs for each individual mouse were summed. 
 
3.2.3 Results and Discussion 
 
We first confirmed that RBC nanosponges could be used to effectively 
neutralize the harmful biological activity of proteins secreted by MRSA strain 
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USA300. Using a hemolytic secreted protein (hSP) fraction collected from bacterial 
culture supernatant via ammonium sulfate precipitation, it was demonstrated that 
preincubation with a sufficient amount of RBC nanosponges could effectively 
eliminate the hSP's lytic effects on RBCs (Figure 3.2.2A). From the data, ≈400 µg 
of nanosponges could be used to neutralize 15 µg of the protein, and this ratio was 
used to fabricate an hSP‐loaded nanosponge vaccine formulation, termed 
nanotoxoid(hSP), for further study. According to dynamic light scattering 
measurements, the size of the nanotoxoid(hSP) was slightly larger and the surface 
zeta potential was less negative when compared to the blank nanosponges without 
hSP loading, both suggesting the association of the hSP with the membrane‐coated 
nanoparticle substrate (Figure 3.2.2B,C). Transmission electron microscopy 
confirmed that, after protein loading, nanotoxoid(hSP) still exhibited a 
characteristic core–shell structure [36, 37],  with a membrane layer surrounding the 
polymeric core (Figure 3.2.2D). 
While previous versions of nanotoxoids have worked with individual, 
purified toxins [12, 38],  the advantage of the present approach is its ability to entrap 
and neutralize pathogen‐specific virulence factors from a protein preparation with 
unknown composition. To validate this concept, we probed the nanotoxoid(hSP) 
formulation for the presence of known virulence factors by immunoblotting 
(Figure 3.2.2E). Of the three different antigens that were analyzed, all were easily 
detectable on the nanotoxoid(hSP). These included α‐toxin, a major MRSA 
virulence factor that has previously been successfully neutralized using RBC 
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nanosponges [17], as well as Panton–Valentine leukocidin (PVL), a white blood 
cell attacking toxin expressed in most community‐acquired MRSA variants [39, 
40],  and γ‐toxin, a bicomponent toxin formed from combinations of three different 
monomers [41].  Quantitative western blot analysis demonstrated that α‐toxin, 
PVL, and γ‐toxin contributed to 11.0% ± 0.7%, 8.7% ± 0.8%, and 5.6% ± 0.2% of 
the total bacterial protein, respectively (see Experimental Section). After subjecting 
the nanotoxoid(hSP) to a wash step, the three toxins remained strongly present 
(Figure 3.2.2F). Additionally, the toxins remained mostly bound to the 
nanoparticles even after dialyzing against physiological buffer for 48 h 
(Figure 3.2.2G), which suggested stable and efficient complexation and explained 
the ability of the nanoparticles to neutralize the toxins' hemolytic activity. 
Given the robust binding of the toxins with the nanosponges, we further 
sought to evaluate the safety of the nanotoxoid(hSP) formulation in various 
settings. First, we compared the hemolytic capacity of hSP in its native form, when 
subjected to rigorous heat denaturation, and when in nanotoxoid(hSP) form 
(Figure 3.2.3A,B). Native hSP demonstrated complete lysis while nanotoxoid(hSP) 
fabricated with an equivalent amount of hSP had almost no activity; this 
neutralization effect has previously been shown to be exclusive to membrane‐
coated nanoparticles [17].  As expected, blank nanosponges were not hemolytic, 
but it was striking that, even after boiling the hSP for 4 h, 40% of its hemolytic 
activity was still preserved. While specific toxins secreted by MRSA are known to 
be heat‐labile [38],  the results demonstrated that the more complex hSP preparation  
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contained elements that were not sensitive to temperature. The data also hint that 
nanosponge‐based neutralization, despite its nondenaturing approach, may also be 
more universally applicable. The results were mirrored when the same formulations 
were incubated with bone‐marrow‐derived dendritic cells (Figure 3.2.3C). The hSP 
preparation completely killed the cells in vitro, and the heat‐treated proteins also 
Figure 3.2.2: Synthesis and characterization of hemolytic‐secreted‐protein (hSP)‐
loaded nanotoxoid, denoted nanotoxoid(hSP). A) Hemolysis of RBCs when incubated 
with varying amounts of hSP in the absence or presence of 400 µg of RBC nanosponges 
(n = 3; mean ± SD). B) Size of RBC nanosponges and nanotoxoid(hSP) as measured 
by dynamic light scattering (n = 3; mean ± SD). C) Surface zeta potential of 
nanosponges and nanotoxoid(hSP) (n = 3; mean ± SD). D) Transmission electron 
microscope image of nanotoxoid(hSP) negatively stained with uranyl acetate (scale bar 
= 100 nm). E) Dot blots probing for α‐toxin, PVL, or γ‐toxin in hSP, blank 
nanosponges, nanotoxoid(hSP), or nanotoxoid(hSP) subject to a wash step. F) Relative 
band intensities of western blots probing for α‐toxin, PVL, or γ‐toxin in 
nanotoxoid(hSP) or nanotoxoid(hSP) subject to a wash step (n = 3; mean ± SD). G) 
Retention of α‐toxin, PVL, or γ‐toxin on nanotoxoid(hSP) after dialyzing against 1 × 
PBS for 48 h (n = 3; mean ± SD). 
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had significant toxicity, leading to only 20% of the cells remaining viable. On the 
other hand, both the nanotoxoid(hSP) and blank nanosponges showed no signs of 
cytotoxicity, again demonstrating the ability of nanocomplexation to much more 
effectively eliminate the harmful biological effects of the toxins. 
In vivo, we assessed potential toxicity by administering the different 
formulations subcutaneously followed by histological analysis after 48 h 
(Figure 3.2.3D). Hematoxylin and eosin (H&E) staining showed that native hSP 
induced significant atrophy in the squamous epithelium and scattered bleeding in 
the dermal as well as subcutaneous tissues. Disarrangement and degeneration of 
collagen fibers were also observed. The toxicity of the protein was further 
demonstrated by TUNEL staining, which revealed widespread apoptosis 
throughout. In contrast, there was no obvious skin damage in the other three 
samples; the structure of the skin remained intact and orderly with minimal signs 
of apoptosis. While the heated hSP displayed considerable toxicity in vitro, the in 
vivo results suggest that the partial attenuation afforded by the heat treatment was 
sufficient to prevent it from reaching the threshold required for inducing significant 
damage in a more complex biological setting. Given the relative safety of the heat‐
treated hSP demonstrated here, we elected to employ it as a control in subsequent 
functional studies as a comparison against nanotoxoid(hSP). 
Following the safety evaluation, the ability of the nanotoxoid(hSP) 
formulation to elicit potent humoral immunity was studied. The induction of 
germinal centers within lymph nodes is one of the critical steps in the immune  
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response against infection, and it is in these regions where affinity‐based maturation 
of B cells occurs [42]. To study the effect of the different formulations on this 
phenomenon, draining lymph nodes were collected 21 d after immunization and 
analyzed for the presence of B cells with the corresponding phenotype 
(Figure 3.2.4A,B). Flow cytometric analysis revealed that, of the different 
formulations, only the nanotoxoid(hSP) could significantly raise the percentage of 
B cells with the germinal center marker GL‐7, with the value increasing to 44% 
Figure 3.2.3: In vitro and in vivo safety studies. A) Comparison of hemolysis induced 
by hSP, heat‐treated hSP, blank nanosponge, and nanotoxoid(hSP) (n = 3; mean ± SD). 
B) Representative images demonstrating the varying degrees of hemolysis in the 
samples from (A). C) Comparison of bone‐marrow‐derived dendritic cell viability after 
24 h of incubation with hSP, heat‐treated hSP, blank nanosponge, or nanotoxoid(hSP) 
followed by another 48 h of culture (n = 4; mean ± SD). D) Hematoxylin and eosin 
(H&E) and TUNEL staining of skin samples collected from untreated mice or from 
mice 48 h after subcutaneous injection of hSP, heat‐treated hSP, blank nanosponge, or 
nanotoxoid(hSP) (scale bars = 100 µm). 
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compared with 19% for the blank control. This was also evident by 
immunofluorescence staining of histological sections, which indicated the presence 
of several nodules with a high concentration of GL‐7+ cells in the lymph nodes of 
mice from the nanotoxoid(hSP) group. Of note, heat‐treated hSP did not result in 
the formation of germinal centers despite delivering the same antigenic material. 
Additionally, blank nanosponges had no effect, precluding any adjuvanting 
contributions from the nanoparticle vector itself and suggesting a favorable 
biocompatibility profile [38]. From the data, it appears that the particulate delivery 
of undenatured bacterial hSP facilitates the generation of strong immune responses.  
To test how the increased response to the nanoformulation would translate 
into antigen‐specific immunity, we quantified the titers generated against known 
Figure 3.2.4: Germinal center formation. A) Flow cytometric analysis of cells at the 
draining lymph node 21 d after administration with blank solution, heat‐treated hSP, 
blank nanosponge, or nanotoxoid(hSP) (n = 4; mean ± SD). Cells were first gated on 
the B220+IgDlow population and values are expressed as percentage GL‐7+. B) 
Fluorescent images of draining lymph node histological sections stained with 
antibodies against B220 (green), IgD (blue), and GL‐7 (red) at different magnifications 
(top: 4× objective, scale bar = 500 µm; bottom: 20× objective, scale bar = 100 µm). 
***p < 0.001, ****p < 0.0001, one‐way ANOVA. 
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constituents present on the nanotoxoid(hSP), including α‐toxin, PVL, and γ‐toxin 
(Figure 3.2.5A–C). To compare the different antigen‐containing formulations, mice 
were vaccinated with a prime injection plus two boosts on days 7 and 14. On day 
21, around the peak of IgG responses, the serum was sampled and titers analyzed 
by indirect enzyme‐linked immunosorbent assays (ELISAs). For α‐toxin, which is 
one of the most highly secreted by MRSA, there was an easily detectable difference 
in antibody production. This is consistent with previous reports on a nanotoxoid 
formulated with purified α‐toxin [12, 38].  Heat‐treated hSP was approximately two 
orders of magnitude less effective. For PVL, 57% of the mice exhibited highly 
elevated titers when vaccinated with the nanotoxoid(hSP), while the other portion 
were nonresponders. This represented a large improvement compared with the 
heat‐treated hSP group, which had titer values near baseline. While the results for 
γ‐toxin were less pronounced, the effect of nanotoxoid(hSP) vaccination still 
bordered on significance. It appeared that the trend in titer production reflected the 
relative amounts of each toxin in the hSP preparation. In total, the nanotoxoid(hSP) 
formulation was more adept at eliciting antitoxin immune responses compared with 
the heat‐treated protein formulation, despite both delivering the same antigenic 
material. 
Finally, we evaluated the effectiveness of nanotoxoid(hSP) vaccination in 
preventing live bacterial infection by employing MRSA strain USA300 in two  
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separate in vivo models reflective of how the disease presents in the clinic [43, 
44].  For both studies, mice were vaccinated with a prime injection plus two boosts 
on days 7 and 14. On day 35 after the first administration, mice were challenged 
with bacteria, and the impact of antivirulence immunity on bacterial survival was 
assessed. In the subcutaneous model, which mimics the skin infections common to 
MRSA[45], the nanotoxoid(hSP) had a striking effect on skin lesion formation 
(Figure 3.2.6A). On the final day of the study, those receiving the nanotoxoid(hSP) 
had, on average, a threefold smaller affected area compared to mice vaccinated with 
heat‐treated hSP. Similarly, the nanotoxoid(hSP) performed well in controlling 
bacterial growth upon intravenous injection, which was used to model potentially 
life‐threatening systemic MRSA infections [46]  (Figure 3.2.6B,C). Looking at the 
Figure 3.2.5: Multivalent antibody responses in vivo. Mice were vaccinated with blank 
solution, heat‐treated hSP, or nanotoxoid(hSP) on day 0 with boosts on days 7 and 14. 
On day 21, the serum was sampled and analyzed for the presence of IgG antibody titers 
against A) α‐toxin, B) PVL, and C) γ‐toxin (n = 7; geometric mean). *p < 0.05, **p < 
0.01, ****p < 0.0001, one‐way ANOVA. 
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total bacterial load 3 d after challenge, mice vaccinated with the nanotoxoid(hSP) 
were able to much more effectively clear out the MRSA bacteria compared to those 
receiving heat‐treated hSP. At the organ level, the effect was most apparent in the 
heart, lungs, and especially the kidneys. Overall, the results are a reflection of the 
differences seen in titer production among the formulations and highlight the 
stronger immunity generated by the nanotoxoid(hSP) formulation, which inhibits 
the ability of the bacteria to survive over time. 
Figure 3.2.6: Protection against challenge with live bacteria. Mice were vaccinated 
with blank solution, heat‐treated hSP, or nanotoxoid(hSP) on day 0 with boosts on days 
7 and 14. A) Lesion size over time after subcutaneous challenge with MRSA USA300 
on day 35 (n = 7; mean ± SEM). B) Total bacterial load summed from major organs 3 
d after intravenous challenge with MRSA USA300 on day 35 (n = 7; geometric mean 
± SEM). C) Individual, weight‐normalized bacteria counts in major organs from (B) 
(n = 7; min to max). *p < 0.05, **p < 0.01, ***p < 0.001, one‐way ANOVA. 
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3.2.4 Conclusion 
 
In conclusion, we have reported on a method of fabricating on‐demand 
nanotoxoids for use as vaccines against pathogenic bacteria. The nanoformulation 
was able to entrap virulence factors from protein preparations of unknown 
composition, was safe both in vitro and in vivo, and could elicit functional immunity 
capable of combating live bacterial infections. Despite containing the same 
bacterial antigens, the nanotoxoid(hSP) formulation consistently outperformed a 
denatured protein preparation in all of the metrics studied, which underscores the 
utility of biomimetic nanoparticle‐based neutralization and delivery. Overall this 
strategy helps to address major hurdles in the design of antivirulence vaccines, 
enabling increased antigenic breadth while maintaining safety. Looking forward, 
the workflow presented here can easily be modified for application toward a variety 
of different pathogens. It may be possible to employ personalized culture isolates 
or to change culture conditions such that virulence factor production is modulated. 
Alternatively, nanotoxoid formulations can be screened to identify a broadly 
neutralizing option that is effective across multiple bacterial strains. Other 
purification or fractionation strategies can be tested to emphasize nonhemolytic 
virulence factors, and different membrane substrates derived from other cell types 
can be leveraged [47-49].  The inclusion of immunological adjuvants can also be 
considered to further boost efficacy [50-52].  Ultimately, the success of 
antivirulence vaccines may help to control the spread of many deadly diseases and 
abate the rising threat of antibiotic‐resistant bacteria. 
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Chapter 3, in full, is a reprint of the material as it appears in Advanced 
Functional Materials, 2016, Fei Wang, Ronnie Fang, Brian Luk, Che-Ming Hu, 
Soracha Thamphiwatana, Diana Dehaini, Pavimol Angsantikul, Ashley Kroll,  
Zhiqing Pang, Weiwei Gao, Weiyue Lu and Liangfang Zhang, and Advanced 
Materials, 2017, Xiaoli Wei, Jie Gao, Fei Wang, Man Ying, Pavimol Angsantikul, 
Ashley Kroll, Jiarong Zhou, Weiwei Gao, Weiyue Lu, Ronnie Fang and Liangfang 
Zhang. The dissertation author was a major contributor and co-author of these 
papers. 
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Chapter 4 
Platelet Membrane-Coated Nanoparticles 
as “Nanosponges” for 
Autoantibody Clearance 
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4.1 Introduction 
 
Platelets, also known as thrombocytes, are a blood component that is essential 
for maintaining hemostasis. One of their main functions is to stop bleeding via 
initiation and propagation of the coagulation cascade [1, 2]. Platelet count is 
universally regarded as the key indicator of bleeding risk, and the normal range in 
healthy people sits between 150,000 and 450,000 platelets per microliter of blood. 
A count under the normal range, termed thrombocytopenia, can be due to either 
decreased platelet production or increased platelet destruction. Clinically, the 
disease can manifest itself as purpura, a delay in the normal process of clotting, and 
spontaneous or excessive bleeding. When platelet counts drop substantially lower 
than normal values, internal hemorrhaging can occur, a severe condition that can 
potentially be fatal [3]. 
Immune thrombocytopenia purpura (ITP), which is oftentimes also referred 
to as idiopathic thrombocytopenic purpura, is an immune-mediated hematological 
disorder characterized by low level of platelets and easy or excessive bleeding due 
to the presence of anti-platelet autoantibodies [4, 5]. These pathological antibodies 
bind to specific antigens on the platelet surface, leading to sequestration and 
destruction by the reticuloendothelial system. The age-adjusted prevalence of ITP 
is estimated to be 9.5 per 100,000 persons in the United States [6]. While the 
condition may appear secondary to a known autoimmune condition or infection, 
oftentimes the underlying etiology is unclear [7-9]. Given this fact, chronic ITP is 
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classically treated using nonspecific therapies such as corticosteroids. While 
capable of eliciting a rebound in platelet levels in many patients, such treatments 
are susceptible to relapse and can cause unwanted side effects  [5, 10]. For those 
that fail to respond to frontline treatments, invasive and irreversible splenectomy is 
a common intervention, but has the chance of postoperative complications such as 
infection, bleeding, and hospitalization [11, 12]. Other second- and third-line 
treatments include intravenous immunoglobulin (IVIg) [13], intravenous Rho 
immunoglobulin (RhIg) [14], rituximab (anti-CD20) [15], and thrombopoietin 
receptor agonists [16]. Most carry significant iatrogenic risk given their generally 
non-specific modes of action. With the probability of high side effects, treatment 
can ultimately be more burdensome than the original disease. With these 
considerations in mind, the development of a treatment modality that can 
specifically target the pathological moieties responsible for ITP is highly desirable. 
Cell membrane-coated nanoparticles represent an increasingly popular 
platform for a variety of applications, including drug delivery [17], vaccination [18, 
19], and detoxification [20, 21]. A significant factor behind their appeal is the 
ability to replicate the surface properties of different cell types faithfully on 
nanoparticle surfaces. Employing biological materials through a top-down coating 
approach bestows synthetic nanoparticles with native cell functionalities. For 
example, it has been shown that coating with red blood cell membrane actively 
modulates residence time in the bloodstream via the display of self-markers that are 
recognized by the immune system [22]. Functionalization with platelet membrane 
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enables biomimetic targeting by taking advantage of the natural interactions 
between platelet surface markers and different targets, including damaged 
vasculature and pathogens [23, 24]. Given the wide range of biological interactions 
that natural cell membranes participate in, the potential of cell membrane-coated 
nanoparticles extends far beyond traditional nanodelivery applications. One such 
area is biodetoxification where the membrane coating serves as an ideal substrate 
for interaction with biological toxins, enabling their neutralization and subsequent 
clearance. For example, red blood cell membrane-coated nanoparticles have 
previously been shown to bind and clear both bacterial toxins [20]  as well as small 
molecule poisons [21]. 
Here, we demonstrated the use of platelet-derived membrane as a natural 
biomaterial for the design of nanoparticulate decoys that can effectively bind and 
clear the pathological antibodies responsible for ITP (Figure 4.1). The binding 
capacity and specificity of platelet membrane-coated nanoparticles (PNPs) were 
evaluated before studying the neutralization capacity of PNPs against anti-platelet 
antibodies both in vitro and in vivo. Finally, an antibody-induced murine model of 
ITP was employed in order to assess treatment efficacy. As a possible new 
treatment for ITP, PNP administration holds distinct advantages compared to 
current therapies. By using the natural substrate of the pathological agent, the 
treatment is highly specific, which may prevent the immune compromising side 
effects commonly seen with other treatments. Further, by diverting anti-platelet 
antibodies away from healthy platelets, PNPs directly act to preserve normal 
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hemostatic function. Ultimately, employing this biomimetic nanoparticle system 
for the specific treatment of ITP may serve to improve patient outcomes in the 
clinic. 
 
Figure 4.1: Schematic of platelet membrane-coated nanoparticles (PNPs) for the 
treatment of immune thrombocytopenia purpura (ITP). (A) To fabricate PNPs, the 
plasma membrane from fresh platelets is derived and then coated onto poly(lactic-co-
glycolic acid) (PLGA) polymeric nanoparticle cores, transferring the surface antigenic 
material from the original cells onto the outside of the nanoparticles. (B) Without 
treatment, ITP is characterized by the binding of pathological autoantibodies to healthy 
platelets, resulting in their clearance by the reticuloendothelial system. (C) When PNPs 
are administered, they act as decoys that bind to the pathological autoantibodies, 
neutralizing them from circulation and enabling the survival of healthy platelets. 
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4.2 Experimental Methods 
 
4.2.1 Animals 
 
Male CD-1mice (6-week old; 20–24 g body weight) were purchased from 
Harlan Laboratories. All animal experiments were performed in accordance with 
NIH guidelines and approved by the Institutional Animal Care and Use Committee 
(IACUC) of the University of California, San Diego. 
 
4.2.2 Platelet Isolation and Membrane Derivation 
 
 Whole blood was collected from male adult CD-1 mice (Harlan 
Laboratories) via puncture of the submandibular vein with 
ethylenediaminetetraacetic acid (EDTA; USB Corporation) as the anticoagulant. 
To isolate platelets, the blood was first centrifuged at 300g for 5 min at room 
temperature. The supernatant then was collected and spun at the same speed for 
another 5 min. The resulting supernatant, representing a platelet rich plasma, was 
then centrifuged at 2000g for 4 min in order to pellet down the platelets, which were 
resuspended in water, aliquoted, and stored at −80 °C for further use. Platelet 
membrane was derived by a repeated freeze-thaw process. A frozen aliquot of 
purified platelets was allowed to thaw at room temperature, centrifuged at 
21,000g for 7 min, and the pellet was resuspended in water. The platelet suspension 
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was refrozen, and the process was repeated three times. The pellet was finally 
resuspended in water, and the membrane protein concentration was quantified 
using a commercial BCA assay (Pierce). 
 
4.2.3 Preparation and Characterization of Platelet Membrane-Coated 
Nanoparticles (PNPs) 
 
PNPs were prepared using a previously reported sonication method [24]. 
Polymeric nanoparticle cores were prepared using carboxyl acid-terminated 
0.67 dL/g 50:50 poly(DL-lactic-co-glycolic acid) (PLGA; LACTEL Absorbable 
Polymers) in a nanoprecipitation process. A volume of 1 mL of a 10 mg/mL PLGA 
solution in acetone was added rapidly to 4 mL of water. The acetone was then 
allowed to evaporate under vacuum for 3 h. PNPs were prepared by fusing platelet 
membrane onto PLGA cores via sonication using a Fisher Scientific FS30D bath 
sonicator at a frequency of 42 kHz and a power of 100 W for 2 min. The size and 
zeta-potential of PNPs were measured by dynamic light scattering (DLS) using a 
Malvern ZEN 3600 Zetasizer. To study the morphology of PNPs by transmission 
electronic microscopy (TEM), samples were deposited onto a 400-mesh carbon-
coated copper grid (Electron Microscopy Sciences) and negatively stained with 
vanadium (Abcam). 
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4.2.4 Platelet Membrane to Nanoparticle Ratio Optimization 
 
To optimize the platelet membrane to PLGA core ratio, PNPs were 
synthesized at membrane-to-core weight ratios ranging from 0.125 to 2 at a final 
polymer concentration of 1 mg/mL. PLGA cores without membrane coating were 
included as a control. The sizes of each set of particles were first measured by DLS 
immediately after synthesis. Afterwards, the particle solutions were adjusted to 
1 × PBS by adding an equal volume of 2 × PBS and the particle sizes were 
measured again. An increase in size upon introduction of PBS was used as an 
indicator of particle instability. 
 
4.2.5 In Vitro Binding Capacity and Specificity Studies 
 
To evaluate the in vitro binding capacity of PNPs, 10 μg of the 
nanoparticles was mixed with different amounts (2, 4, 8, 16, 32, 64, and 128 μg) of 
fluorescein isothiocyanate (FITC)-labeled polyclonal anti-mouse thrombocyte 
antibodies (Lifespan Biosciences). The precise antigen specificity of the antibodies 
was unknown. After mixing the PNPs with antibodies, the fluorescence intensity of 
the fluorescently labeled antibody was measured using a Tecan Infinite M200 plate 
reader. The mixtures were incubated for 10 min at 37 °C, then centrifuged at 
21,000g for 8 min to pellet the PNP/anti-platelet complexes. The fluorescence 
intensity of the supernatant was measured and used to calculate the amount of 
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antibody that had bound to the PNPs. To evaluate binding specificity, either 10 μg 
of PNPs or 10 μg of polyethylene glycol-functionalized nanoparticles (PEG-NPs) 
[25] were mixed with 32 μg of FITC-labeled antibody. To test the binding capacity 
in serum, 10 μg of PNPs were incubated with 128 μg of FITC-labeled antibody in 
either PBS or 50 vol% mouse serum. 
 
4.2.6 In Vitro Neutralization 
 
For the pre-incubation study, 20 μg of FITC-labeled anti-platelet antibody 
was incubated with varying amounts of PNP (5, 10, 20, 50, and 100 μg) or PBS at 
37 °C for 15 min. The mixture was then added to a solution containing the number 
of platelets equivalent to 40 μg worth of membrane material and incubated at 37 °C 
for 15 min. For competitive co-incubation study, the same amounts of PNPs and 
antibody were concurrently added to the platelets. All samples were then washed 
by centrifugation at 2000g three times with PBS. The amount of antibody binding 
to platelets was measured by flow cytometry on a Becton Dickinson FACSCanto 
II flow cytometer and analyzed using Treestar FlowJo. 
 
4.2.7 In Vivo Binding Stability 
 
To establish a mouse model of thrombocytopenia, 6-week old CD-1 mice 
were injected intraperitoneally with PBS or 50 μg of anti-thrombocyte antibody. 
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The mice were bled before injection as well as 4 h and 24 h after injection for 
platelet enumeration. Male 6-week old CD-1 mice were injected intraperitoneally 
with either 50 μg of anti-mouse thrombocyte antibody (Lifespan Biosciences) pre-
incubated with 100 μg of PNPs, 50 μg of antibody alone, or PBS. Blood was 
sampled by submandibular vein puncture both before and 24 h after injection using 
EDTA as the anticoagulant. To enumerate the platelets, a 1 μL volume of blood 
was diluted 1000 times in 1% bovine serum albumin (Sigma Aldrich) in PBS. The 
diluted solution was then stained with FITC-labeled anti-mouse CD41 (Biolegend) 
for labeling of platelets, and flow cytometry was used to count the number of 
FITC+ events per given volume. 
 
4.2.8 In Vivo Treatment 
 
Male 6-week old CD-1 mice were injected intraperitoneally with 50 μg of 
anti-thrombocyte antibody to induce thrombocytopenia. After 15 min, mice 
received either 400 μg of PNPs, 400 μg of PEG-NPs, or PBS via tail vein injection. 
Blood was sampled both before and 24 h after administration of antibody. To assess 
the effect of treatment on bleeding time, mice were first anesthetized 24 h after 
antibody administration with a cocktail of 150 mg/kg ketamine (Zoetis) and 
10 mg/kg xylazine (Lloyd Laboratories). For the bleeding time assay, a tail segment 
5 mm from the distal end was excised by a sterile blade, and the cut end of the tail 
was immediately placed into 37 °C saline solution in a 50 mL tube. The time from 
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amputation to complete cessation of bleeding was recorded for each mouse. Those 
mice bleeding longer than a pre-determined time limit of 20 min were euthanized 
immediately. 
 
4.3 Results and Discussion 
 
PNPs were prepared by fusing mouse platelet-derived membrane onto the 
surface of poly(lactic-co-glycolic acid) (PLGA) nanoparticle cores [24]. In brief, 
platelets collected from whole blood were subjected to repeated freeze-thaw cycles 
and centrifugation in order to obtain purified membrane. The membrane was then 
coated onto the surface of preformed PLGA nanoparticles by a sonication process. 
After the membrane coating, dynamic light scattering indicated an approximately 
20 nm increase in the average hydrodynamic diameter over that of the bare PLGA 
cores (Figure 4.2A). Zeta potential measurements also suggested successful 
coating, as evidenced by the increase in surface charge of the coated nanoparticles 
to approximately the same level as a membrane vesicle only sample (Figure 4.2B). 
Moreover, transmission electron microscopy of negatively stained PNPs revealed 
a characteristic core-shell structure with a layer of membrane coated over the 
polymer core (Figure 4.2C). In order to optimize the membrane coating ratio, PNPs 
were prepared using different membrane to PLGA core weight ratios ranging from 
0.125 to 2 (Figure 4.2D). After adjusting to 1 × phosphate buffered saline (PBS) 
solution, which represents physiological salt concentrations, bare PLGA cores with 
 
 
 160 
no membrane coating aggregated immediately due to charge screening effects. 
With increasing amounts of membrane, there was a trend of decreasing aggregation. 
At a ratio of 1 to 1, no apparent size increase was observed, and this formulation 
was chosen for further studies. The particles also demonstrated little change in size 
and distribution when subjected to high shear conditions. 
 
Figure 4.2: Characterization and optimization of PNPs. (A) Hydrodynamic size of 
bare PLGA cores, platelet vesicles, and PNPs as measured by dynamic light scattering 
(n = 3; mean ± SD). (B) Surface zeta potential of bare PLGA cores, platelet vesicles, 
and PNPs (n = 3; mean ± SD). (C) Transmission electron microscopy images of PNPs 
negatively stained with vanadium (scale bar = 75 nm). (D) Sizes of PNPs fabricated 
with varying membrane protein to PLGA weight ratios measured both immediately 
after synthesis in deionized water and after adjusting to 1 × PBS buffer solution (n = 3; 
mean ± SD). 
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To investigate the binding capability of PNPs to anti-platelet antibodies, 
10 μg (polymer weight) of PNPs were incubated with different amounts of 
fluorescently labeled polyclonal anti-platelet antibodies ranging from 2 μg to 
128 μg (Figure 4.3A). Quantification based on the fluorescent signal showed a 
linear increase in antibody binding at lower concentrations, after which the binding 
plateaued. From the plotted data, it was interpolated that 50% binding occurred at 
a polyclonal antibody input of approximately 25 μg. The experiment was also 
repeated keeping the amount of antibody constant while varying the PNP 
concentration. To assess the specificity of the PNP-antibody interaction, binding 
was compared to a control polyethylene glycol-functionalized lipid-polymer hybrid 
nanoparticle (PEG-NP) [25]  (Figure 4.3B). Using an equivalent amount of either 
PNPs or PEG-NPs, it was demonstrated that, comparatively, the PEGylated 
nanoparticles exhibited the near absence of antibody binding. The different results 
observed between the two types of nanoparticles indicate that the platelet 
membrane bestows specific binding properties. Additionally, an isotype antibody 
not specific to platelet membrane also showed no binding to the PNPs. 
Furthermore, to evaluate the effect of the presence of other proteins, the binding of 
antibody to PNPs was tested in the presence of mouse serum (Figure 4.3C). 
Compared with binding in PBS, there was little difference observed for the sample 
tested in serum, indicating the potential of the nanoparticles retain their function 
within the complex biological environment found in vivo.  
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To characterize the ability of PNPs to neutralize anti-platelet 
antibodies in vitro, different amounts of PNPs ranging from 0 to 100 μg were pre-
incubated with a constant amount of fluorescently labeled anti-platelet antibodies. 
This was followed by the addition of fresh platelets to the mixture and analysis of 
antibody binding to the platelets by flow cytometry (Figure 4.4A and B). It was 
shown that fluorescent signal sharply decreased with increasing amount of PNPs. 
Using 20 μg of polyclonal anti-platelet antibodies, it was observed that 
approximately 5–10 μg of PNPs were able to reduce mean fluorescence intensity 
by 50%, a ratio that was in line with what was observed from the antibody binding 
study. To evaluate the neutralization capacity in a competitive setting, both PNPs 
and fresh platelets were simultaneously incubated with the antibodies (Figure 4.4C 
Figure 4.3: In vitro binding of anti-platelet antibodies to PNPs. (A) Fluorescent 
quantification of anti-platelet antibody binding to PNPs. A constant amount of PNPs 
(10 μg) was incubated with varying amounts of fluorescently labeled antibodies (n = 3; 
mean ± SEM). (B) Relative binding of anti-platelet antibodies to either PNPs or 
PEGylated nanoparticles (PEG-NPs) (n = 3; mean ± SD). (C) Relative binding of anti-
platelet antibodies to PNPs in either PBS or mouse serum (n = 3; mean ± SD). 
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and D). In this scenario, mean fluorescence intensity was halved at approximately 
20 μg of PNPs using 20 μg of antibodies. The antibody signal on the platelets 
decreased slower with increasing PNP concentration compared with the pre-
incubation scenario, reflecting the increased challenge in neutralizing antibodies 
when both nanoparticle and fresh platelets compete for binding at the same time. 
Despite this fact, a great deal of neutralization capacity was still observed, 
indicating strong potential for therapeutic use.  
Figure 4.4: In vitro neutralization of anti-platelet antibodies by PNPs. (A) 
Representative flow cytometry histograms of platelets labeled with fluorescent anti-
platelet antibodies pre-incubated with varying amounts of PNPs (from left to right: 100, 
50, 20, 10, 5, and 0 μg). (B) Mean fluorescence intensity of the samples in (A) (n = 3, 
mean ± SD). Ctrl = no antibody. (C) Representative flow cytometry histograms of 
platelets labeled with fluorescent anti-platelet antibodies while concurrently incubated 
with varying amounts of PNPs (from left to right: 100, 50, 20, 10, 5, and 0 μg). (D) 
Mean fluorescence intensity of the samples in (C) (n = 3, mean ± SD). Ctrl = no 
antibody. 
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After confirming that PNPs could neutralize anti-platelet 
antibodies in vitro, their binding stability in vivo was assessed (Figure 4.5). To 
conduct the experiment, a previously established murine model of immune 
thrombocytopenia was employed [26]. When anti-platelet antibodies alone were  
administered intraperitoneally, their diffusion across the peritoneal membrane 
induced very obvious thrombocytopenia. Platelet counts dropped dramatically even 
4 h post-injection and the challenged mice exhibited a more than 90% reduction in 
platelet counts 24 h post-injection. When the antibodies were pre-incubated with 
PNPs, followed by injection of the mixture, platelet counts were preserved to levels 
not statistically different from those of mice administered with only blank solution. 
The results suggest a strong binding interaction of the anti-platelet antibodies with 
the PNPs, which prevents the release of the pathological antibodies and thereby  
preventing their ability to cause the clearance of healthy platelets. The ability of the 
PNPs to maintain antibody neutralization within the complex in vivo biological 
environment was encouraging and motivated further study on the ability of the 
nanoparticles to perform this function in situ in a therapeutic setting. 
Finally, the ability of PNPs to be used as a means for the therapeutic 
treatment of immune thrombocytopenia in vivo was assessed. Mice were first 
intraperitoneally administered a bolus dose of anti-platelet antibodies capable of 
causing a marked reduction of platelet counts. This was followed by intravenous 
administration of either blank solution, PEG-NPs, or PNPs. Blood was sampled 
both before and 24 h after challenge with anti-platelet antibodies, and platelet count  
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was determined (Figure 4.6A). Without any treatment, platelet counts dropped 
dramatically after 24 h and were approximately 10% of their original value. A 
similar drop was seen when mice were treated with PEG-NPs, which could not bind 
the antibodies and were unable to rescue platelet counts. In contrast, those mice 
treated with PNPs exhibited a marked increase in preservation of platelet number 
with final values at approximately 70% of pre-challenge values. 
In order to demonstrate the importance of this platelet preservation on 
maintenance of hemostatic capacity, a bleeding time test, which is a commonly 
used in vivo assay for evaluating platelet function, was carried out (Figure 4.6B). 
After tail tip excision and immediate immersion into a warmed saline solution, the 
amount of time to bleeding cessation was recorded. For unchallenged mice, the 
Figure 4.5: In vivo neutralization of anti-platelet antibody activity by PNPs. Mice were 
intraperitoneally administered with PBS, anti-platelet antibodies, or the antibodies pre-
incubated with PNPs (n = 8; mean ± SEM). Blood was collected both before and 24 h 
after administration to quantify platelet counts. ***P < 0.001, NS = not significant, 
Student's t-test. 
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bleeding stopped on average between 1 and 2 min after excision, whereas those of 
anti-platelet antibody-challenged mice with no treatment exhibited increased 
bleeding times of at least 5 min; more than half of the untreated mice bled longer 
than a predetermined threshold of 20 min. The same level of bleeding was seen for 
those mice treated with PEG-NPs, whereas those treated with PNPs had bleeding 
times that were consistent with the unchallenged group. The results of the bleeding 
time assay correlate with the post-challenge platelet counts for each group and 
demonstrate that the amount of platelets retained in PNP-treated mice is sufficient 
to retain full hemostatic capabilities. This is in line with previous research that 
platelet counts need to decrease below a certain threshold in order to translate to 
increased bleeding times [27]. The treatment efficacy results here confirm the 
ability of PNPs to bind and neutralize pathological antibodies in circulation, thus 
preserving the function of healthy platelets. 
ITP is a hematological disorder characterized by a decreased number of 
circulating platelets, which generally manifests as an increased tendency to bleed 
as well as susceptibility to bruising. While this can generally affect quality of life, 
severe cases can have serious consequences, such as the induction of intracranial 
hemorrhaging that carries with it a high mortality rate [28, 29]. The 
thrombocytopenic condition is very often acute and, in most cases, patients 
spontaneously recover platelet levels within a short period time without any specific 
treatment [30]. However, a small proportion may develop chronic ITP, which 
usually occurs in adults and is characterized by persistence of significantly low  
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platelet counts for longer than 6–12 months. Unfortunately for patients suffering 
from chronic ITP, the disease commonly occurs in response to an unknown 
stimulus [31], making effective treatment a difficult task for clinicians. Drugs that 
either modulate or distract the immune system are generally employed, including 
the use of corticosteroids or IVIg as frontline therapies [32]. Splenectomy is the 
approach often taken after failure of initial treatment and can lead to the restoration 
of the platelet counts to a normal level by removing the organ responsible for both 
clearance of opsonized platelets and pathological antibody production [33]. The 
procedure, however, can be associated with infection, bleeding, hospitalization, and 
vascular complications [11, 12]. Moreover, a splenectomy is irreversible and can 
likely lead to long-term impairment of hematologic and immunological functions 
Figure 4.6: In vivo treatment of antibody-induced thrombocytopenia by PNPs. Mice 
were intraperitoneally administered with anti-platelet antibodies, followed 15 min later 
by intravenous injections of either blank solution, PNPs, or PEG-NPs via the tail vein. 
(A) Blood was collected both before and 24 h after administration to quantify platelet 
counts (n = 8; mean ± SEM). (B) Bleeding time from the tail vein into PBS. An upper 
time limit of 20 min was established prior to initiation of the study. ***P < 0.001, 
Student's t-test. 
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[12, 34]. Other secondary or tertiary treatment options exist, including use of 
cytotoxic drugs, platelet transfusions, and thrombopoietin receptor agonists among 
others. To our knowledge, none of the current available therapies directly address 
the pathological moieties that contribute directly to the clearance of healthy 
platelets from circulation. 
To create a platform capable of specific autoantibody depletion for the 
treatment of ITP, platelet membrane was directly employed in order to fabricate 
nanoparticles that mimic the surface properties of the original cell [17, 22]. One 
major advantage of this approach is that the nanoparticle surface serves as a natural 
substrate for autoantibodies against endogenous cellular targets [35]. Further, the 
nanoparticles present the relevant epitopic targets recognized by the antibodies 
without the need to identify antigen specificity, which can vary among patients 
[36]. Cell membrane-coated nanoparticles have previously demonstrated favorable 
safety profiles in vivo as well as lack of both acute and chronic anti-nanoparticle 
immune responses [19, 37]. Another advantage of the nanoparticulate platform is 
that storage after lyophilization is common practice [24], significantly extending 
shelf-life compared with whole platelets, which need to be carefully processed and 
expire within a week after collection [38]. 
In the present study, in vitro binding of PNPs to anti-platelet antibodies was 
demonstrated to be both stable and specific. According to the information obtained 
from Figure 4.3A, the apparent weight binding ratio between PNPs and the anti-
thrombocyte antibody was approximately 1:5. However, the antibody preparation 
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that we employed was polyclonal, and  only about 15% of the antibody was actually 
specific to platelet membrane. Based on the information from these two pieces of 
data, we calculated that one PNP could sequester around 280 platelet membrane 
specific anti-thrombocyte antibodies. Pre-incubation and binding of antibodies to 
the nanoparticles appeared to preclude further interaction with platelets, a result 
that was confirmed in vivo. Impressively, the PNPs performed well in a competitive 
setting. As shown in Figures 4.4 C and D, 20 μg of PNPs, which contain 20 μg of 
platelet membrane material, was able to reduce binding of antibodies to platelets 
by half, despite the fact that they were in the presence of 40 μg worth of membrane 
material from the native platelets. This suggests that nanoparticulate membrane 
may have an inherent advantage in binding that can be exploited for other 
biodetoxification applications. Administration of PNPs in a therapeutic scenario 
demonstrated considerable efficacy, and a bleeding time assay was used to 
highlight the importance of preserving platelet counts. Compared with a 93% drop 
in platelet count for the PEG-NP treatment group, PNPs preserved 70% of the 
platelets, presumably due to their ability to bind the pathological antibodies and 
remove them from circulation. The results are not likely due to any thrombotic 
effect from the PNPs, as it has been demonstrated that the particles are absent most 
intracellular activating factors. Given the relative scarcity of platelets in the blood, 
it should be feasible to administer enough nanoparticles to significantly outnumber 
healthy circulating platelets. While the long-term consequences of administering 
cell membrane-derived antigenic material in a nanoparticulate format have yet to 
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be fully explored, it should be noted that platelet transfusion is a well-established 
clinical procedure; it can be reasonably expected that administration of membrane 
material only should be less burdensome given the lack of the biologically active 
components present in the intracellular compartment of intact platelets. 
 
4.4 Conclusion 
 
In conclusion, we have successfully demonstrated the application of PNPs 
towards the treatment of ITP. The nanoparticles showed the ability to specifically 
bind anti-platelet autoantibodies, which are directly responsible for reducing 
platelet counts. Upon binding, it was demonstrated that the interaction between the 
PNPs and the antibodies was strong, effectively neutralizing biological 
activity in vivo. In an antibody-induced thrombocytopenia animal model, mice 
treated with PNPs after challenge with antibodies were able to retain their platelet 
counts. Further, in a bleeding time assay, mice treated with PNPs exhibited normal 
hemostasis via effective clot formation, and average values were nearly identical to 
unchallenged controls. On the other hand, untreated mice or those administered 
with control nanoparticles bled excessively due to lowered platelets counts and 
impaired hemostasis capacity. The ability to specifically neutralize anti-platelet 
antibodies in ITP presents a new option in the current landscape of treatment for 
the disease. Currently, most therapies are non-specific and can significantly impair 
broad immune function. By targeting the pathological antibodies directly, it may be 
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possible to treat the disease while leaving the immunity intact, giving patients an 
increased opportunity for natural recovery of platelet counts without damaging and 
irreversible interventions. Alternatively, PNPs may also be used as an adjuvant 
therapy to either synergize with current treatments or enable a decrease in drug 
dosages to help limit unwanted side effects. Ultimately, PNPs represent a promising 
platform for the treatment of ITP and further study towards translation is warranted. 
Chapter 4, in full, is a reprint of the material as it appears in Biomaterials, 
2016, Xiaoli Wei, Jie Gao, Ronnie Fang, Brian Luk, Ashley Kroll, Diana Dehaini, 
Jiarong Zhou, Hyeon Woo Kim, Weiwei Gao, Weiyue Lu and Liangfang Zhang. 
The dissertation author was a major contributor and co-author of these papers. 
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Chapter 5 
Conclusions 
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5.1 Cancer Cell Membrane-Coated Nanoparticles for 
Anticancer Vaccination 
 This chapter reported on the fabrication of a biomimetic, nanoparticulate 
anticancer vaccine that is capable of codelivering autologously derived tumor 
antigen material together with a highly immunostimulatory adjuvant. The 
nanovaccine was rationally designed to present the two major components, the 
tumor antigens and the adjuvant, in a way that enhances their ability to promote 
efficient antigen presentation and activation of downstream immune responses. The 
formulation takes advantage of the small size of nanoparticles for lymphatic 
drainage and uptake into antigen presenting cells, and the endosomal uptake route 
was complemented by choosing an adjuvant with an endosomal receptor. Further, 
the cancer cell membrane coating allows for the delivery of multiple tumor antigens 
to drive a multi-antigenic immune response as a strategy to overcome the tumor 
heterogeneity that is often responsible for partial treatment responses or recurrence. 
Ultimately, it is demonstrated that the nanovaccine can elicit potent antitumor 
immune responses in vivo, including dendritic cell maturation and T cell expansion. 
When combined with additional immunotherapies such as checkpoint blockades, 
the formulation demonstrates substantial therapeutic effect. Overall, the work 
exemplifies using nano-immunoengineering to create a novel anticancer vaccine 
that can later be extrapolated for the development of personalized, autologous 
anticancer vaccines with broad applicability.  
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5.2 Development of Red Blood Cell Membrane-Coated 
Nanoparticles as “Nanotoxoid” Antivirulence Vaccines 
 Red blood cell membrane-coated nanoparticles (RBCNP or “nanotoxoid”) 
have great potential as a nanotoxoid vaccine by improving the deactivation and 
delivery of pore forming toxins for effective antivirulence immune responses. By 
mimicking the surface of red blood cells, the RBCNP serves as a decoy to absorb 
pore-forming toxins that are commonly secreted by pathogenic bacteria as a 
mechanism to cause cellular damage and increase virulence. Within the nanotoxoid 
formulation, the toxins are detained to reduce damage to the host while also being 
presented to the immune system in an undenatured form as antigens  
In the chapter’s first example, the efficacy of a biomimetic nanoparticle-
based antivirulence vaccine is examined in a mouse model of methicillin-
resistant Staphylococcus aureus (MRSA) skin infection. Vaccination with 
nanoparticle-detained staphylococcal α-hemolysin (Hla) caused strong in vivo 
immune responses including germinal center formation and high anti-Hla serum 
titers. This immune response provided protection against MRSA skin infection 
through both reduced lesion size and reduced bacterial load.  
 This concept was then extended in the second example of the chapter by 
using MRSA supernatant, which contains a multitude of pore-forming toxins, to 
make the nanotoxoid (nanotoxoid(hSP)). Using this in situ strategy, a 
multiantigenic nanotoxoid was made to improve vaccine potency by introducing a 
breadth of antigenic targets for more complete immunity formation. Compared to 
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a traditional anti-toxin vaccination consisting of heat-denatured MRSA 
supernatant, the nanotoxoid(hSP) caused the formation of higher anti-toxin titers 
for multiple different toxins. The improved immune response led to superior 
protection in both a MRSA skin infection model and an intravenous model. 
Importantly, no significant damage was caused by the nanotoxoid in vitro or in vivo. 
Overall, both examples show the utility of using the red blood cell membrane-
coated nanoparticle for concurrent entrapment of toxins as the antigenic vaccine 
component in a manner that is both safe and highly immunogenic. Notably, this 
novel vaccination system is a way to combat bacteria without the use of antibiotics, 
which is important when antibiotic resistance is an increasing global concern.  
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5.3 Platelet Membrane-Coated Nanoparticles as 
“Nanosponges” for Autoantibody Clearance 
 In the fourth chapter, platelet membrane-coated nanoparticles are used as 
an immunomodulatory treatment for immune thrombocytopenia purpura (ITP). 
Pathological anti-platelet autoantibodies characteristic of ITP cause a reduction in 
platelet counts that can lead to uncontrolled bleeding which can be fatal. In the 
study, the use of platelet membrane-coated nanoparticles (PNPs) is explored as a 
therapy to specifically clear anti-platelet antibodies. The platelet membrane coating 
confers the nanoparticles with an outer surface displaying the full array of native 
platelet surface protein. In this way, it acts as a decoy to strongly bind the 
pathological antibodies that are specific to the platelet surface proteins. The ability 
of the nanoparticles to neutralize the autoantibody activity was shown 
both in vitro and in vivo. Ultimately, we leverage the antibody binding of PNPs to 
therapeutically treat a mouse model of antibody-induced thrombocytopenia. 
Treatment with the PNPs was efficacious in reducing antibody-mediated 
destruction of actual platelets, which allow for reduced bleeding in a bleeding time 
assay. The platelet membrane-coated nanoparticles exemplify a promising platform 
for specifically treating antibody-mediated immune thrombocytopenia by acting as 
a decoy for anti-platelet antibodies and preserving circulating platelets while 
leaving general immune functions intact. This platform can also potentially be 
expanded to address other autoimmune disorders that involve autoantibodies 
against specific host cells.  
